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1. Introduction and aims 
Peptides have very important role in bioregulation as hormones, neurotransmitters, 
neuromodulators, etc. In the organism, biologically active peptides are present at very low 
concentrations (e.g. in 10"10 M in the blood plasma), and their metabolism are strictly 
regulated. If the concentration of a biologically active peptide increases in an uncontrolled 
manner, it can cause serious problems in the bioregulation. Under normal conditions, 
proteolytic enzymes cleave peptides very rapidly. However, in several cases, the 
overproduction or defective clearance of peptides causes serious illnesses. The brain is highly 
sensitive to long-lasting elevated concentrations of neurotransmitters or neuropeptides. It can 
be stated that some neuropeptides, which have important physiological roles, are neurotoxic 
in high concentrations. Alzheimer's disease (AD) is an example for the neurotoxicity of a 
peptide, (3-amyloid peptide (AP). 
Our aims were as follows: 
1. to optimize the synthesis of AP peptides, peptide fragments and modified Ap peptides 
2. to investigate the biological effects of AP peptides in various biological assays 
3. to design and synthesize peptides which inhibit the neurotoxic effect of Ap (functional 
antagonists); to test them in cell culture 
4. to investigate the stability of AP peptides under physiological conditions and to establish 
applicable peptide handling for in vivo and in vitro experiments. 
5. to characterize the secondary structure and the aggregation state of Ap peptides. 
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2. Theoretical background 
2.1 Theories about Alzheimer's disease 
There is a significant increase in the prevalence of disorders affecting elderly people, 
as more and more people reach old age. Few subjects in biomedicine have aroused the interest 
of the scientific and lay communities alike as has Alzheimer's disease (AD). The dramatic 
rise in life expectancy during the 20th century, from roughly 49 years to more than 75 years in 
the USA and countries of the western world, has resulted in a burgeoning number of 
individuals achieving the age of at which neurodegenerative disorders become common. The 
most common form of age-related neurodegenerative disorders is AD. It was first described 
by the German physician Alois Alzheimer in 1907 [1]. Multiple molecular, cellular, 
structural, and functional changes occur in the brain during aging. Neural cells may respond 
to these changes adaptively, or they may succumb to neurodegenerative cascades that result in 
disorders such as AD [2]. 
One of the major neuropathological characteristics of AD is the extracellular 
accumulation of P-amyloid peptides (AP) in neuritic plaques [3,4,5,6]. Ap is normally 
secreted by neurons and can be found in low concentrations in cerebrospinal fluid (CSF) [7,8] 
and plasma where it is associated with lipoproteins [9,10,11]. However, the physiological role 
of Ap secretion remains unknown [12,13]. Experimental data indicate that AD affects a wide 
array of neuronal and glial functions and thereby may lead to neuronal death in the nervous 
system. The fatal outcome of exogenous Ap administration in numerous neurotoxicity models 
is well established, but the mechanism is still elusive. 
Amyloid substances are tissue deposits occurring in animals and humans, primarily 
composed of unique proteinaceous fibrils. Deposition of the relatively inert fibrils by different 
pathogenic mechanisms leads to excessive accumulation, with pressure atrophy and death, 
resulting from interference with physiological processes of affected organs. This disease 
complex is referred to as amyloidosis or P-fibrilloses; it occurs in association with 
inflammatory conditions (such as rheumatoid arthritis), and with tumours of various types. 
Aging is thought to occur in association with amyloid deposition in the brain, heart and 
pancreas. Whereas amyloid variants exhibit a broad diversity of amino acid composition and 
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of tissue origin, their common characteristic is the high propensity to form water-insoluble 
pleated aggregates in mammals [14,15,16,17,18,19,20]. In addition to the fibrils, a constant 
constituent of amyloid deposits has been found to be normal serum glycoprotein. 
Polymerisation of relatively low molecular weight amyloid monomers leads to a highly 
ordered peptide folding process yielding high molecular weight aggregates that withstand 
proteolytic degradation. Potentially amyloidogenic proteins are produced in significant 
amounts by several organs [21,22,23]. Prevailing evidence indicates that amyloidogenic 
peptides and proteins exert a wide array of physiological functions under fine-tuned metabolic 
control [24,25,26,27,28]. Mutations and deleterious conditions, however, may dysregulate the 
synthesis and processing of amyloidogenic proteins, compromise their enzymatic degradation, 
and lead to pathological modification of peptide release [29]. Additionally, amino acid 
substitutions in and around the pre-mature amyloidogenic sequence may result in 
pathologically increased secretion of amyloid derivatives and may eventually be accompanied 
by abnormal folding of the proteins [30,31]. Taking these observations into account, it seems 
that pathological conditions boost abnormal amyloid-processing pathways and result in 
abundant generation of highly toxic amyloid derivatives which may be critical for the 
pathogenesis of a broad range of pathophysiologically distinct disorders with signs of 
peripheral and/or central nervous system dysfunction. 
The main histological feature of AD is the presence of extracellular starch-like senile 
plaques [15,32,33,34,35] with different degrees of maturation [36]. Plaque formation persists 
over a long period of time and begins as amorphous, largely non-filamentous aggregates of 
A(3. The initial form is called "diffuse plaque" which can be identified by sensitive silver 
staining methods (e.g., the Gallyas' silver stain). In the next step of maturation, diffuse 
plaques become increasingly fibrillar the plaque is called "neuritic plaque" or "senile plaque". 
It is a denser deposit of fibrillar amyloid with P-sheet structure, and shows thioflavin-S and 
Congo Red staining. Neuritic plaques are often surrounded by degenerating neurites [34,37]. 
Besides AD, formation of AP-containing senile plaques also occurs in Down's syndrome, 
during normal aging, and to a lesser extent after traumatic brain injury [38]. The 
extracellularly located plaques subsequently cause formation of intracellularly located 
neurofibrillary tangles, another essential feature of the AD brain [39]. Neuropathologically, 
AD is characterised by widespread neuronal death in brain regions subserving learning and 
memory formation, like the neocortex, amygdala, anterior thalamus, basal forebrain 
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cholinergic system and monoaminergic brain stem systems. A characteristic pathology occurs 
in hippocampus and medial temporal lobe. Pyramidal neurons are severely affected in AD 
Ap is a proteolytic cleavage product of its precursor, termed amyloid precursor protein 
(APP) (Figure 1.). A(3[l-42] has the following structure: 
Asp-Ala-Glu-Ohe-Arg-His-Asp-Gly-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-
Asp-Val-Gly25-Ser-Asn-Lys-Gly-Ala-Ile31-Ile-Gly-Leu-Met35-Val-Gly-Gly-Val-Val-Ile-Ala 
APP is a transmembrane protein [44] and is expressed as four major isoforms in 
humans, containing 695, 717,751 and 771 amino acid residues [41,42], Generation of Ap 
from the APP requires proteolytic cleavage by two proteases, p- and y-secretase. APP is 
cleaved either by a-secretase resulting in sAPPa (nonamyloidogenic pathway) , which might 
have a neuroprotective role, or by the protease BACE, identified as P-secretase, and then y-
secretase to yield Ap [43]. Determination of the amino acid sequence of Ap made possible the 
identification of APP gene which is located on chromosome 21 [44], Ap exists in two mature 
isoforms in the AD brain: the cerebral vasculature consists of 39-40 amino acid residues 
(Ap[l-40]), senile plaque-forming Ap comprises 42-43 amino acids (Ap[l-42]) [15,45], 
[1,40]. 
A P P 
H O L O P R O T E I N 
a - s e c r e t a s e 
P- s e c r e t a s e 
y - sec re tase 
Figure 1. Structure and cleavage of APP molecule. 
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Diffuse Ap deposits are thought to precede the formation of other neuropathological 
characteristics, involving neurofibrillary tangles [46] and abnormal phosphorylation of 
cytoskeletal proteins [47,48]. Ap directly affects tau-phosphorylation, which may be a critical 
intracellular step of Ap toxicity. The "tau and tangel hypothesis " argues that tangles are in 
fact central to AD. Tangles are comprised in of the microtubule associated protein tau, 
normally expressed in axons but which in AD becomes highly phosphorylated and aggregated 
into abnormal filaments in the cell body. 
2.1.1. Role of APP in brain 
APP represent a family of ubiquitous transmembrane glycoproteins, which span the 
lipid bilayer once and is expressed by activated cells that participate in cell-cell interaction. 
Neurons, the primarily affected cells in AD, are the only cells in brain that basically express 
APP. In neurons, newly synthesised APP is transported along the axon in a kinesin-I-
dependent manner and subsequently and transcytosed to the somatodendritic compartment 
[49]. On the molecular level, APP has binding sites for cell surface receptors and for 
molecules of the extracellular matrix such as collagen, laminin, heparansulfate proteoglycans, 
and glycosaminoglycans (GAG) which suggests a general function for APP in regulation of 
cell and synaptic interactions [50]. APP was also found to bind zinc(II) and copper(II) at two 
distinct sites [51]. Some studies revealed that APP has an enzyme-like activity and reduces 
copper(II) to copper(I) while APP itself undergoes oxidative modification [52,53]. 
2.1.2. Role of aggregation 
Above a threshold concentration, A(3 undergoes highly ordered protein aggregation in 
aqueous solutions resulting e.g. in the formation of senile plaque in AD [30]. Aggregated Ap 
can be detected in low concentrations in the CSF and in the general circulation of AD 
patients, and may not only be the end-product of APP of neural origin but also of blood-bom 
APP [7]. Ap, released in a monomeric form in the extracellular space, begins a self-
aggregation process, which, through the transient formation of several discrete intermediate 
Ap species, leads to Ap condensation as extremely insoluble protein fibrils with characteristic 
morphological features (80- to 150 A fibrils) [30]. Shortly after its release to the extracellular 
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space in nM - pM concentrations, AP may exist as monomer. During the highly ordered 
process of Ap fibrillogenesis, discrete but transient Ap dimers, tetramers and intermediate 
oligomer species (termed protofibrils), exist between the two stable states of Ap, the 
monomelic protein and the fibril. Intermediary protofibrils appear early during fibrillogenesis 
and disappear when fibrils appear [54,55,56,57,58,59]. Low molecular weight Ap (monomers 
and dimers) do not alter the normal metabolic activity of neurons in culture [56]. AP[l-40] 
and Ap[l-42] assemble through analogous steps, although AP[l-42] protofibrils are 
assembled more rapidly. The increased polymerization rate of AP[l-42] may be explained by 
increased hydrophobic interactions, such as by the formation of a longer p-sheet in the C-
terminus, and by folding of this sheet over the assembly core [55]. Aggregated Ap also can be 
detected in low concentration in the CSF and in the general circulation of AD patients [7,60]. 
In vitro aggregation of Ap peptides results in the formation of identical, fibrils with those 
found in AD [61,62,63,64]. While AP[16-20] sequence seems to be essential to AP- Ap 
binding [65], stabilization of the fibrillar state of Ap is confined partly to a P-turn of AP[26-
29] region and to hydrophobic interactions in the 29-42 domain [66,67]. Aggregation of the 
Ap is strongly affected by concentration, pH, temperature, interactions of Ap with essential 
membrane components, low concentrations of Cu2+ and Zn2+ions etc. [68,69]. Study of the 
influence of the different parameters on the aggregational properties of Ap and their synthetic 
analogues can reveal essential data to the prevention of the undesirable transformations. 
Standardization of the aggregation grade of Ap peptides is also essential for reproducible 
biological experiments. 
2.1.3. Decline of the cholinergic system 
Cholinergic neurons of the basal forebrain provide dense projections to the cerebral 
cortex and limbic system [70,71], and thereby modulate memory acquisition, storage and 
retrieval. One of the striking neuropathological markers of AD, is the widespread loss of 
cholinergic neurons of the medial septum and magnocellular nucleus basalis [5]. As the 
decline of cholinergic activity - decreased cholin-acetyltransferase (ChAT) activity and 
inhibition of the acetylcholine (ACh) release-, correlates with the progression of memory 
impairment in AD, the "cholinergic hypothesis of memory dysfunction" was postulated [72]. 
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However, degeneration of cholinergic projection neurons is likely due to the loss of their 
synaptic contacts in post-synaptic target regions, like the hippocampus and neocortex, known 
to be primarily deranged in AD. Other neurotransmitter systems (e.g. serotoninergic, 
noradrenergic, glutamatergic) are also severely affected in AD. 
2.1.4. Inflammation and free radicals 
In the human brain several cell types are capable of initiating and amplifying a brain 
specific inflammatory response involving the synthesis of cytokines, prostaglandins and 
oxygen free radicals. In AD, signs of an inflammatory activation of microglia and astroglia 
are present inside and outside amyloid deposits [73]. Cell culture and animal models suggest 
an interactive relationship between inflammatory activation, reduced neuronal functioning 
and deposition of amyloid [74]. 
Damage to eventually all biomolecules by reactive radicals, particularly by oxygen 
and nitrogen species, is referred to as oxidative stress. The radical-mediated breakdown of 
membrane components is termed lipid peroxidation. [75]. Aging is associated with the 
temporal enhancement of oxidative damage to neurons, and accelerated oxidative neuronal 
damage is evident in AD, an oxidative stress hypothesis was proposed to describe cellular 
events leading to neuronal loss in AD [76,77]. A(3 induces oxidative stress to neurons by 
acting as a free radical following distortions of its electronic structure, by interacting with 
membranous cellular components by its lipophylic nature, and by initiating receptor-mediated 
pro-inflammatory signaling pathways. Ap may generate free radicals in aqueous solution [78]. 
The presence of Met residue at position 35 of Ap was regarded as pivotal: substitution or lack 
of Met-35 significantly abrogates Ap toxicity, free radical formation and protein oxidation 
[79,80]. 
2.1.5. Receptor-binding theory 
Exposure of nerve, glial and endothelial cells to Ap causes modification of a wide 
variety of cellular functions, which differ depending on the stereochemical characteristics, 
aggregation state, and concentration of the Ap fragment applied. While at nM - pM range Ap 
concentration promote neuronal differentiation and increase neuronal viability [28,81,82], Ap 
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is toxic to neurons at |jM range and induce necrotic [83] or apoptotic cell death [84,85] in a 
dose-dependent fashion. For low concentrations of Ap, a direct neuromodulatory role 
affecting cholinergic neurotransmission in the brain was proposed [86,87]. In vivo 
investigations indicated neurotoxic properties of pM AP concentrations on cholinergic 
neurons of the basal forebrain [88,89]. It was assumed that Ap exerts its pathologic effects 
through cell-surface receptors. Since AP destabilises the intracellular Ca2+ homeostasis 
[90,91], and augments the generation of reactive oxygen species (ROS) [92,93], a number of 
receptors were proposed as molecular targets for Ap. Exposure of nerve cells to Ap activates 
Ca2+ permeable receptor channels which results an increase of intracellular Ca2+ concentration 
[29]. Excessive activation of NMD A subclass of glutamate receptors was reported to lead to 
excitotoxic neuronal death under pathological conditions [94,95]. Besides neuronal receptors, 
endothelial and glial receptor subclasses were also recognized as pivotal for the uptake and 
transcytosis of Ap at the BBB from the general circulation [96] and for the activation of 
inflammatory mechanisms in the brain [97]. In this regard, the receptor for advanced 
glycation endproducts (RAGE), which is a member of the immunoglobulin superfamily of 
cell-surface molecules, and the type A macrophage scavenger receptor (MSR/A) received 
much attention [98,99,100]. 
2.1.6. The aluminium theory 
One decade ago, it was hypothesized that aluminum plays a role in the etiology of 
Alzheimer's disease. Because this theory could not be proved, the scientific opinion refused it 
by now. There are results suggesting that the total amount of exposure and lifetime 
occupational exposure to aluminium are not likely to be important risk factors for 
Alzheimer's disease [101]. None of the extensive European and American case-control 
studies have found a relationship between AD and aluminum antacids intake. 
2.1.7. Risk factors 
The epidemiological study of AD with special emphasis on its genetic causes provided 
us with important findings and a very detailed knowledge of the risk factors of the disease in 
the past few years. The following risk factors were found: 
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a. Age is the most important risk factor for dementias of all kinds. The prevalence of AD 
shows an exponential rise with age. The number of cases double in every 5 years in the 
population aged over 65 years [102], 
b. Genetic causes constitute the second most important risk factor for the disease [102], 
Different genetic factors contribute to AD, some of them being directly and invariantly 
causative of the disease, producing familiar AD (FAD). 
Clinically typical AD can cluster in families and can specifically be inherited in an 
autosomal dominant fashion. Determining how frequently genetic factors underlie the disease 
is difficult in a late-onset disorder such as AD. Moreover, the clinical manifestations are 
generally quite similar or almost indistinguishable from those of the sporadic cases, although 
some families may show distinctive clinical signs [103]. The recognition that polymorphic 
alleles of apolipoprotein E (apoE) can predispose strongly to the development of AD in the 
60s and 70s suggests that other polymorphic genes could predispose to the disorder but would 
be difficult to detect in genetic epidemiological studies, because they do not always produce 
the disease and will thus not show high penetrance [104,105,106,107], 
The first specific genetic cause of AD to be identified was the occurrence of missense 
mutations in APP [108], Despite extensive genetic surveying, such mutations have only been 
confirmed in some two dozen or so families world-wide. Now, 4 well established genes are 
associated with AD (Table 1.). 
Chromosome Gene Defect Phenotype 
21 ß-APP mutations Î Production of all Aß peptides or Aß [1-40] peptides 
19 ApoE4 polymorphism Î Density of Aß plaques and vascular deposits 
14 Presenilin 1 mutations t Production of Aß [1-42] peptides 
1 Presenilin 2 mutations Î Production of Aß [1-42] peptides 
Table 1. Genetic factors predisposing to Alzheimer's disease: relationships to the Afi phenotype. 
c. Precipitating factors: the existence of certain situations is often found in the prehistory of 
AD patients. The most important ones are the following factors: 
- lack of education [102,109]; 
- head injury (defined as one sufficient to produce unconsciousness) up to 30 years prior 
to the onset of AD, either accidental or repeated [110,111]; 
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- some illnesses, including depression (occurring at 10 or less years before AD onset), 
atherosclerosis, coronary disease, diabetes and hypothyroidism, were also shown to increase 
the prevalence of AD. 
2.1.8. Diagnostics for AD 
AD described clinically as a progressive, degenerative and irreversible process, is only 
one of the diseases that cause dementia. Therefore diagnostics would be important to rule out 
treatable diseases other then AD (e.g. hypothyreosis, depression, psychosis, head trauma, 
neurosyphilis, tumours, B12 vitamin deficiency, etc.) and to enable the initiation of an 
adequate therapy. Although numerous clinical signs have been described, there are no 
satisfactory, sensitive, and specific clinical tests for AD so far, unambiguous evidence can 
provide only the histopathological autopsy. Diagnostics may become even more important in 
the future as subtypes of AD may be teased out that respond better to particular therapeutic 
strategies. 
The Alzheimer's Disease Society described in 1998 seven stages in progress of AD: in 
the first stage, there is no apparent cognitive decline, the third stage is described as a state 
with mild cognitive decline, getting lost, low performance, concentration deficit, and the 
seventh stage characterised by late dementia. 
Clinical attempts focus especially on the possible earliest diagnosis. For example there 
are studies that suggest in patients with mild cognitive impairment, olfactory identification 
deficits, particularly with lack of awareness of olfactory deficits, may have clinical utility as 
an early diagnostic marker for AD [112]. 
2.1.9. Prevention and therapy attempts 
There are only few treatments available to improve cognitive and behavioural 
symptoms, as well as therapies that may slow the progression of the disease somewhat 
(cholinesterase inhibitors, nicotinic and muscarinic acetylcholine receptor ligands, and other 
cognitive enhancers), but there is no cure for AD. Soon after the definition of numerous 
fundamental factors that may contribute to the development and progression of AD, including 
- without attempt of full coverage - genetic factors [113], apoE polymorphism [114], 
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cholinergic decline [115], x hyperphosphorylation [116], Ap toxicity, AP aggregation and P-
sheet breaker (BSB) peptides, the search for potential neuroprotective intervention yielded 
several distinct directions [117,118]. 
Epidemiological studies have documented a reduced prevalence of AD among users of 
some nonsteroidal anti-inflammatory drugs (NSAIDs) [119,120], (such as ibuprofen, 
indomethacin, and sulinac sulfin). This effect seems not to be mediated by inhibition of 
cyclooxygenase activity [121]. Aspirin (the best known NSAID) had an unconvincing effect 
in epidemiological studies. Similarly, other classes of anti-inflammatory compound (e.g. 
hydroxy-chloroquine or prednisone) did not show benefits to AD patients [122]. Vitamin E as 
a lipid-soluble antioxidant has been reported to slow functional loss in AD patients. Vitamin 
C, another antioxidant, might be a potential inhibitor of neuritic plaque formation 123]. 
Application of Ca2+ antagonists is favoured on the recognition that Ap initiates a rapid 
elevation of [Ca ]j [124,125]. Several studies indicate that women who take oestrogen after 
menopause have an unexpectedly low incidence in AD [126]. 
One potential route for therapy involves the immunization of patients against the Ap. 
Resulting from earlier research on transgenic mice [127], Elan Pharmaceuticals began clinical 
trials of a vaccine, AN-1792. But some scientists warn that AN-1792 could cause a dangerous 
autoimmune response in humans [128]. 
The possibility of neuroreplacement therapies in case of neurodegenerative disorders 
(such as AD and Parkinson's) is supported by the existence of neuronal stem cells in the adult 
human brain [129]. 
2.2. Stability studies of Ap peptides 
Stability studies are very important in drug research: as more peptides and proteins are 
targeted to be used as drugs, their propensity toward degradation should be examined and 
appropriate stabilising modifications made as required. "Aging" of Ap peptides is a common 
method before in vivo experiments [130,131,132]; this is a long (1-3 days) aggregation 
process at pH=7.4 for fibril formation. In vitro investigations of Ap neurotoxicity in cell and 
tissue cultures proceed for several hours or even days [133,134] at pH=7.4, 37 °C. 
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Deamidation of asparagine (Asn) residues, to yield (iso-aspartic) or a - aspartic acid 
(Asp) residues in place of the original Asn, is a major nonenzymatic degradation pathway for 
many proteins [135,136]. This intrinsic instability of Asn is proposed to serve as a "molecular 
clock". Oxidation of metionin (Met) also could occur. 
3. Materials and methods 
3.1 Synthesis and purification of peptides 
All peptides were synthesised by solid phase technique, mostly manually, but in some 
cases on ABI 430A (Applied Biosystems Co.) automated peptide synthesiser, using Boc- or 
Fmoc-chemistry. We applied a new version of the standard Fmoc-chemistry, therefore this 
new method will be more detailed described in the Results. Most peptides were synthesised 
with amidated C-terminus, but some of them were prepared with free carboxyl C-terminus, 
depending on the linker of the used resin. Protected amino acids and resins were purchased 
from Bachem and used without further purification. Protected amino acids used in the 
syntheses were of the L-configuration. Coupling agents were from Richelieu Biotechnologies 
(HOBt) or from Fluka (DCC). TFA was from Fisher Scientific, and the remaining reagents 
from Aldrich. Solvents (DCM, DMF, CH3OH and CH3CN) were from Merck. 
3.1.1. Peptide synthesis by Boc chemistry 
The syntheses involving Boc-chemistry of peptides with amidated C-terminus were 
carried out on MBHA resin. Peptides with free carboxyl group at the C-terminus were 
synthesized on Merrifield resin. The first amino acid was coupled to the Merrifield resin using 
an oil bath at 70 °C for 48 hours. The following side-chain protections were used: Arg(Tos), 
Asp(OcHex), Glu(OcHex), His(Z), Lys(2ClZ), Ser(Bzl), Tyr(2BrZ); the side chains of Asn 
and Gin were unprotected. 
In case of manual synthesis, the coupling reactions were achieved with a 3-fold excess 
of Boc-amino acids with DCC (3 equiv.) as activating agent in DCM or DCM - DMF (1:1) or 
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performed HOBt ester for Asn and Gin in order to avoid side-reactions. After a coupling time 
of 2 hours, the completeness of acylation was monitored at each stage by Kaiser's standard 
ninhydrin test [137]. The test reaction is quick and easy to carry out, but some deprotected 
amino acids (Asn, Asp, Ser and Pro) do not show the typical dark blue colour. For monitoring 
the coupling and deprotection of Pro residues, the choranil test was used [138]. In cases where 
incomplete coupling was found, the coupling procedure was repeated or acetylation was 
carried out before the removal of the N^-amino protecting group prior to the coupling of the 
next amino acid. Acetylation was performed with 30% acetic anhydride in DCM for 10 and 
20 minutes. Intermediate Boc removal was achieved with 50% TFA in DCM (containing 
0.5% dithiothreitol, if Met was present in the peptide sequence) followed by neutralisation 
with 10% TEA in DCM. After completion of the synthesis and removal of the Na-Boc 
protecting group from amino-terminus, some peptides were acylated with propionic acid or 
with succinic acid using symmetrical anhydride method. Final deprotection as well as the 
cleavage of the peptides from the resin were performed with anhydrous hydrogen fluoride in 
the presence of 8% anisol, 2% dimethylsulfide, 2% p-cresol and 2% thiocresol as scavengers 
at 0 °C for 60 min. For 1.0 g peptide-resin 10 ml HF was used. After the removal of the 
hydrogen fluoride under a stream of nitrogen and in vacuum, the free peptides were 
precipitated with diethyl ether, filtrated, washed with diethyl ether and extracted with 50% 
aqueous acetic acid (short peptides) or with 95% TFA (long peptides), diluted with water, and 
lyophilised. 
3.1.2. Purification of peptides 
After lyophilization, about 150 mg crude peptide was purified by using a Shimadzu 
LC-8A preparative HPLC system. A PrePak 300x47 mm VYDAC column packed with CI8 
silica gel (300 A pore size, 15-20 pm particle size) for short peptides and a Backbond WP C4 
column (300x47 mm, 300 A pore size, 15-20 pm particle size) for long peptides. The column 
was eluted usually with a solvent system consisting of (A) 0.1% aqueous TFA and (B) 0.1% 
TFA in 80% aqueous ACN in a linear gradient mode. For semipreparative scale purification a 
Knauer HPLC apparatus (Knauer GmbH.) with a variable wavelength UV detector was used, 
equipped with a Nucleosil 300 C4 (16x280 mm, 300 A pore size, 10-20 pm particle size) for 
long peptides or with a BST SI-100S lOCig semipreparative column for short peptides. For 
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FT-IR spectroscopy, peptides were purified with a solvent system consisting of (A) 0.05 M 
NH4OAc and (C) 0.05 M NH4OAc in 60% ACN. Extinction was monitored usually at X = 220 
nm. The fractions were checked by analytical HPLC and those with purity higher than 95% 
were pooled and lyophilised and stored at -20 °C. 
3.2. Analytical characterisation of peptides 
3.2.1. Analytical HPLC 
A Knauer HPLC apparatus was used for analytical HPLC control of the peptides 
equipped with a Lichrosorb 5RP-Cis (250 mm x 4 mm) reversed-phase analytical column or 
with a Nucleosil-300 C4 (250 mm x 4 mm) reversed-phase analytical column for peptides 
containing more than 20 amino-acids. 
3.2.2. Amino acid analysis 
About 500 pg samples of purified peptides (with purity more than 95%) in sealed 
glass tubes and vacuum were hydrolysed in 6N HC1 for 24 h at 110 °C. The analysis were 
done on a Hewlett-Packard Amino Quant automatic amino acid analyser, equipped with an 
Amino Quant Cis (200 mm x 2.1 mm) hipersyl column, using OPA (ortho-phthalo-
dialdehyde) derivatization. 
3.2.3 Mass spectrometry (MS) 
Electrospray ionisation (ESI) mass spectra were recorded on a FinniganMat TSQ 7000 
mass spectrometer. Fast atom bombardment (FAB) mass spectra were obtained on a modified 
FinniganMat 212/AMD 5000 double-focusing mass spectrometer and a VG-ZAB 2SEQ 
hybrid tandem mass spectrometer, both equipped with a liquid secondary ion mass 
spectrometer source (Cs+ ion gun). 
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3.2.4 Liquid chromatography combined with mass spectrometry (LC-MS) 
For stability investigations, LC-MS measurements were carried out in order to identify 
all peptide fragments formed during the incubations in vials. The contents of vials were 
lyophilised for a tender concentration. The HPLC apparatus was equipped with a Nucleosil 
300 A 5Ci8, 2X100 mm analytical column, gradient 0-»60% B over 30 min, eluted with A = 
0.1% TFA and B = 70% ACN + 0.1% TFA at flow rate of 0.2 ml/min. Extinction was 
monitored at X = 220 nm. The outlet of HPLC apparatus was connected to the inlet of the 
ESI-MS apparatus (FinniganMat TSQ 7000 mass spectrometer). MS scans in the necessary 
M/z+ ranges (typically 150 to 2000) were performed every 2 seconds. 
3.3. Secondary structure investigation of PA peptides: FT-IR spectroscopy 
FT-IR spectra were performed on a Nicolet Impact 410 spectrometer. The peptides 
were dissolved in HFIP (hexafluoro-2-propanol) or in DMSO and then diluted with phosphate 
buffered saline. 
3.4. Stability investigations of Ap [25-35] 
3.4.1. Incubation of Ap[25-35] 
The stability investigation of Ap[25-35] peptide was carried out at 37°C in double-
distilled, ion-exemptioned water, under physiological conditions at pH = 7.4 and in pH = 8.0 
phosphate buffer made of double-distilled, ion-exemptioned water in the presence and without 
CaCl2. In both cases the concentration of AP[25-35] (with purity higher then 99%) was 0.1 
mM. The composition of the physiological solution was: NaCl 144.0 mM, KC1 4.0 mM, 
CaCl2 1.8 mM, NaH2P04 0.33 mM, MgCl2 0.53 mM and HEPES buffer (active in the pH 
range 6.0-8.5) 5.0 mM. In order to prevent biological degradation, 0.02 % of NaN3 was used 
in the experiments. The solutions were pipetted into sterilised vials with single-used sterile 
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syringes; then the vials were sealed. Samples were taken in every hour for one day and then 
daily. 
3.4.2. Product analysis 
The HPLC-analysis of the samples was carried out by using an analytical Knauer 
HPLC system equipped with a Lichrosorb 5RP-18 (250 mm x 4 mm) reversed-phase column. 
The column was eluted with a solvent system consisting of (A) 0.1% aqueous TFA and (B) 
0.1% TFA in 80% aqueous ACN in linear gradient mode (0 - 60% B in 30 minutes, flow 1.0 
ml/min). The eluent was monitored at 220 nm. The different peaks were collected into vials, 
lyophilised and identified by electrospray mass spectrometry (ES-MS, FinniganMat TSQ 
7000 mass spectrometer). 
3.5. Biological investigations of A0 peptides 
3.5.1. Cell culture, treatment, and fluorescence measurements 
Primary cultures of rat astrocytes were prepared from the cerebral hemispheres of 
new-bom rats by mechanical dissociation. The cells were plated onto glass coverslips pre-
treated with poly-L-ornithin and fibronectin, and were placed on 12-well culture dishes and 
cultured for 4-6 weeks at 37 °C in humidified 5% CO2 atmosphere. At this stage, about 95% 
of the cells were positive by immuno-cytochemical staining. The cells on coverslips were 
exposed to 1 pmol/1 final concentration of the different PA peptides for 8 hours. Intracellular 
loading of Fura-2-AM was attained by incubating the cells with 2 pM Fura-2-AM during the 
final 30 min of the 8-hour, 37 °C incubation period. The cells on coverslips were then washed 
and the coverslips were transferred to cuvettes containing Hepes Buffer Tyrode at 25 °C for 
measurements. Fluorescence measurements in standard lxl cm cross section quartz cuvettes 
were performed with a Hitachi F-2000 spectro-fluorimeter. Ratiometric fluorescence 
determinations were utilised excitation at 340 and 380 nm, using emission wavelength of 495 
nm at 10 nm bandwidths and the 367 nm-excitation was taken as a Ca2+ -insensitive 
wavelength [139]. 
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3.5.2. Investigations of peptides by microdialysis in vivo 
For experiments young adult male Whistar rats were used: a concentric microdialysis 
probe was implanted into the right MBN at standard co-ordinates. Inlet and outlet tubes of the 
probe were run through a liquid swivel to allow collecting dialysis samples from freely 
moving conscious animals. Dialysis was started 24 h after probe implantation. Artificial 
cerebrospinal fluid (ACSF) served as vehicle throughout the experiments. Both A(3[l-42] and 
the peptide with code ZM6 were used in equimolar concentration (200 pM) and solubilized in 
ACSF to which 0.1% TFA had been added; vehicle + TFA-dialysed animals served as 
controls. After an equilibration period, ZM6 was infused for 60 min, which was followed by a 
40 min infusion of Ap[l-42]. Outflow fractions were collected to determine the excitotoxic 
action of AP[l-42] and its prevention by equimolar ZM6. Extracellular amino acid levels 
were determined by HPLC analysis. 
3.5.3. Behavioural tests 
Novelty-induced spontaneous activities of the animals were assessed 24 h post-surgery 
[140]. Each test lasted for 3 min, during which latency to the start of exploration, the degree 
of horizontal ambulation, and the number and total time a rat spent in an upright position were 
recorded. Animals were also tested for discriminative learning in a one-way step through 
passive avoidance task 14 days post-surgery. In the training trial (day 12) the animals were 
placed in an illuminated chamber to explore the boxes. The latency to step into the dark 
compartment was recorded. On the second day of the test (day 13) a mild foot shock (1mA, 3 
s) was delivered through the grid floor upon entry into the dark compartment. Retesting was 
performed 24 h later(day 14) and the latency to step into the dark chamber was recorded 
(post-shock latency) within a total of 3 min retesting period. 
3.5.4. Measurement of membrane potential changes by flowcytometry 
Immortalized striatal cell cultures of new-born rats (cell line M26-1F) were prepared 
and suspended [141]. 400 pi cell suspension was incubated with 4 pi of peptides (10"4 M) for 
10 min, then 4 pi bis-oxonol was given. The membrane potential of the mixture was measured 
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by flowcytometer after 2 min. Each experiment started and finished with control 
measurements. The measurements were performed at room temperature (22 ± 2 °C) on a 
Coulter EPICS 750 flow sorter supplied with a 14 mW Ar laser (488 nm). The gate number 
was 104 cells. Histograms obtained by representation of cell number vs. fluorescens intensities 
and dot - plot figures were compared and analysed. 
3.5.5. Measurement of the neurotoxic effect of amyloids and the neuroprotective effect of A£-
antagonists with MTT test on SH-SY5 Y neuroblastoma cells 
Ap peptides were dissolved in a medium which did not contain Phenyl-red. These 
stock solutions were sonicated for 10 minutes, then aggregated for 4-5 days at 4 °C (10 
minutes daily sonication) then the stock solution was homogenized. The neuroblastoma cells 
were mechanically agitated in a Phenyl-red free medium then collected in a dish. The cells 
were counted (30000 cells/100 pi), pipetted into sterile Eppendorf vials, then incubated for 3h 
at 37 °C in humidified 5% CO2 atmosphere. The cells were treated with the Ap peptide 
containing stock solutions (warmed up to 37 °C). The treated cell-suspension were pipetted 
into plates containing 96 wells (100 pl/well) and incubated for another 24h at 37 °C in 
humidified 5% CO2 atmosphere. Each well was supplemented with 10 pi MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) stock solution (4 mg/ml PBS). The 
plates were incubated again for another 3h at 37 °C in humidified 5% CO2 atmosphere. The 
cell culture medium was carefully removed from the cells. The MTT treated cells were 
homogenized and then the MTT-formasan was diluted with a 4:1 ratio mixture of 
DMSO/EtOH (100 pl/well). The plates were again sonicated for 10 min. After this procedure 
the cells were measured with an Elisa Reader photometer at 550/620 nm. The results were 
statistically analyzed. 
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4. Results 
4.1. Synthesis and purification of peptides 
Ap 1.40 DAEFRHDGGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV-NHz 
Ap ] .42 D AEFRHDGGYEVHHQKLVFFAED VGSNKGAIIGLMVGGVVAI-NHz 
MOD3 DGEGRHDSGGEEHHQKEGEGGEDEGSNKGAIIGLMEGGEGEG-NHz 
MOD4 DAEFRHDGGYEVHHQKLVFFAEDVGSNKGAAAGAAVGGVVIA-NH2 
AP25-35 GSNKGAIIGLM-NHz 
AP27.35 NKGAIIGLM-NHZ 
Ap28-35 KGAIIGLM-NHz 
AP29.35 GAIIGLM- NH2 
AP31.35 IIGLM-NH2 
AP31-35-OH IIGLM-OH 
AP25.30 GSNKGA-NH2 
Ap25-30-OH GSNKGA-OH 
Ap24-28 SUC-EGSNK-NH2 
ZM6 Pr-IIGL-NHz 
R-ZM6 RIIGL- NH2 
AP-Tjernberg KLVFF-NH2 
KLV6 KLVGF- NH2 
Table 2. Sequences of the synthesized Ap, APP and modified Ap peptides. 
4.1.1. Synthesis of Ap[l-40] peptide with Boc-chemistry 
The synthesis was carried out on an MBHA resin with 0.40 mmol/g substitution. After 
the cleavage of the peptide from the resin with HF, the purification was performed in several 
steps. Poor solubility of the crude peptide and the high tendency of the peptide solution to 
form colloidal or even visible precipitates caused difficulties during the post-cleavage work-
up. To minimise losses, lyophilization and a new dissolution before the first purification was 
avoided. After the post-cleavage work-up, the peptide solution was immediately purified by 
HPLC. To apply the peptides on HPLC column, they were dissolved in 60% ACN in distilled 
water containing 0.1% TFA at 3 mg/ml concentration using sonication. The solution was 
quickly filtered from the resin and diluted threefold with water, filtered through a bed of 
Hyflo, and injected on a Backbond WP C4 cartridge for a first preparative purification. The 
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used gradient was 25% ->35% B in 10 min and then 35% -» 45% B in 30 min. The average 
purity was 60 %. After that 91.5 mg of a peptide fraction with 70% purity was purified with 
semipreparative HPLC, 27.0 mg peptide with 90% purity was obtained. Finally, this 27.0 mg 
peptide was purified as well and gave 6.2 mg peptide with 98% purity. According to 
necessity, additional lyophilised peptide fractions were purified. In the absence of the C4 
semipreparative column the purification was repeated on a BST SI-100S 10Cis 
semipreparative column with a gradient of 30% -> 40% B in 10 min and then 40% -> 70% B 
in 60 min. 
4.1.2. Synthesis of A[3[l-42] peptide with Fmoc-chemistry 
We have found that the main problem of the solid-phase Ap-synthesis is the 
aggregation of the growing peptide chains within the polystyrene beads, which cause 
enormous coupling problems during the synthesis. Coupling should be repeated sometimes 3-
or 4-times for getting a good acylation grade. As a consequence, we have worked out a new, 
optimized method for the synthesis of long Ap peptides. 
As an example, Ap[l-42] was synthesized on trimethoxy-benzhydrylamine resin (Rink 
resin) using standard Fmoc-chemistry (Na-amino protection: Fmoc; side chain protections: 
Bul (Thr, Ser, Tyr), Boc (Lys), Pbf (Arg), Trt (His), OBu1 (Asp, Glu). The only but very 
important change was the use of 10% anisol in all the solvents during all the couplings. 
Anisol (similar to DMSO) can deaggregate the peptide chains also within the polymer bead. 
Using anisol, couplings had not be repeated in most cases, except the middle sequence of the 
molecule, there couplings were repeated. The AP[l-42] was cleaved from the resin with 50% 
TFA in DCM, using 2% H2O and 10% anisol as additives. After cleavage, the peptide 
solution was evaporated in vacuum, then the peptide was precipitated with ether, filtered and 
redissolved in trifluoroethanol (TFE) : water = 2:1 and lyophilized. The crude product 
contained some impurities and was purified on a preparative C-4 Vydac column, using ACN 
gradient 25% -> 35% in 30min. This method gave a very good yield (~15%) and a very pure 
product. 
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4.1.3. Synthesis of peptides MOD3 and MOD4 
MOD3 and MOD4 peptides were designed and synthesized as synthetic analogues of 
the A|3[l-42] and then followed and compared their aggregation to the aggregation of A(3[l-
42]. The MOD3 analogue was designed and synthesised in such sequence, which contains the 
toxic pentapeptide fragment AP[31-35] of the AP[l-42] peptide and the others are mainly 
hydrophilic residues. The MOD4 peptide has the same amino acid sequence as AP[l-42] with 
the exception of the AP[31-35] fragment. The amino acids of the (31-35) fragment had been 
replaced by Ala with the exception of the Gly. Both syntheses were carried out manually 
using Boc-chemistry. First, the crude peptides were purified on preparative HPLC, equipped 
with a Vydac Cis cartridge. The purified peptide fraction with 90% purity was submitted for 
further purification with a solvent system containing 0.05 M NH4OAc instead of 0.1% TFA, 
resulting in a product as an acetic acid salt. The purification was carried out on a Knauer 
HPLC apparatus, equipped with a BST SI-100S 10Ci8 and Knauer Lichrosorb RP18 
semipreparative columns, respectively. The used gradient was 1% -> 20% B in 10 min, and 
then 20% -» 50% B in 70 min. 
4.1.4. Design and synthesis of A(3 fragments: P-sheet breakers (BSBs) and functional 
antagonists 
AP[25-35] shows the whole neurotoxic effect of Ap[l-40] and Ap[l-42] if aggregated 
[82]. On the other hand, the Ap[16-20 ] sequence seems to be very important for aggregation 
('seeding sequence") and the original sequence KLVFF ("Tjernberg peptide") can 
deaggregate Ap peptides or prevent aggregation ("P-sheet breaker", BSB) [65,142]. 
Some years ago we have found a short Ap fragment (31-34) which show a very low 
neurotoxicity, however, in all the in vitro and in vivo tests can prevent the neurotoxic effect of 
Ap[l-42]. This peptide was called as functional antagonist - inverse agonist. The propionyl 
derivative of this short peptide proved to have a better neuroprotective effect (Pr-IIGL; ZM6) 
[143]. Using these peptide sequences KLVFF and Pr-IIGL as lead compounds, we have 
designed and synthesized short pentapeptides in order to have better BSBs and/or better 
antagonists. 
28 
The results were very interesting. If we change only one Phe to Gly in Tjernberg 
peptide, the resulting analog KLVGF shows only a very small BSB activity, however, it 
proved to be one of the best functional antagonist ever synthesized. In MTT-test (in vitro, SH-
SY5Y neuroblastoma cell line) this peptide can protect neurons from the neurotoxic effect of 
A(3[l-42] also in 1:1 molecular ratio (Figure 2.)! This KLVGF peptide serves now as a lead 
compound for further design of Ap antagonists, peptides and peptidomimetics, and this work 
is the subject of a patent. 
On the line we found an arginine analog of ZM6, RIIGL, which proved to be much 
more active antagonist then the mother compound (Figure 2.). The sequence RIIGL serves as 
lead for further design of antagonists (peptides and peptidomimetics) and this work is also 
subject of a patent. 
Summarizing this work, we have found two pentapeptides, which show excellent 
neuroprotective effect as AP-antagonists. 
Figure 2. Optical density measurement of formasan for toxicity investigations of A|3[l-42] 
and the protective effect of AP-antagonists. 
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4.2. Analytical characterisation of peptides 
4.2.1. FT-IR spectroscopy 
The aggregation of Ap peptides were studied under different conditions (pH, 
temperature, concentration, etc.) in order to determine the effects of the conditions that were 
varied in the biological experiments. Since amyloid peptides exist in different conformation 
and aggregation states depending on the circumstances of preparation and purification, a 
standardisation method was applied. Peptides were dissolved in DMSO (which is widely used 
in biological experiments) or HFIP. Such stock solutions can be chosen as a unique reference 
start-point for aggregation and conformational studies, as amyloid peptides have been found 
to be monomelic, with a solvated and unordered (in DMSO), or a-helical (in HFIP) structure 
[144]. Dilution with PBS A at the required pH was used instead of lyophilization and 
redissolution because of the uncertainties in the lyophilization parameters. As time passed, 
upon the addition of PBS A (pD 7.4) to the DMSO solution of Af3[l-40], a conformational 
transition began immediately, resulting in P-sheets, which became more associated and the 
interactions between them grows stronger. AP[l-42] exhibits properties similar to those of 
PA[l-40], but with higher amount of associated P-sheets. The 2D FT-IR studies are in good 
agreement with the finding that AP[l-40] displays less tendency to aggregate than Ap[l-42], 
demonstrating the importance of the C-terminal region in the aggregation. The within 1 h 
random-to-sheet transformation was also demonstrated. 2D FT-IR analysis in the 24 h domain 
shows simultaneous helix-to-sheet and sheet-to-sheet transformation. From this it was 
deduced that the conversion of helical segments to P-sheets is slower than in case of the 
random structures. The intramolecular H-bonds of the a-helices may explain this finding.. 
Studies with samples heated at 90°C indicate the formation of P-sheets with strong H-bonds 
between the molecules. A highly aggregated state of the P-sheets was reached within 15 min, 
after which no change was detected. Samples incubated at 37°C after the heating experiment 
showed the same random-to sheet process as samples that had not been heated. These 
observations led to the conclusions, that AP[l-40] forms P-sheets which are stable even at 
high temperature, and these very stable sheets are formed from intermediate P-sheets. 
However, formation of these intermediate P-sheets is not favoured at 90°C. 
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The 2D FT-IR study demonstrated that the MODS peptide is not able to aggregate at 
all or it aggregates extremely slowly. The aggregation ability of the MODS and the AP[l-42] 
peptides are similar, however MODS shows a small amount of antiparallel P-sheet formation. 
4.3. Biological investigation of Ap peptides 
4.3.1. Intracellular long-term elevation of Ca2+ in rat astrocytes 
The effect of different Ap peptides on the intracellular Ca2+ level was monitored by 
comparative fluorimetric studies of rat astroglial cells grown on coverslips. The cells were 
exposed to 1 pM concentration of the peptides for 8 h. After that, cells were found to be 
labelled satisfactorily with 2 pM Fura-2-AM for 30 minutes at 37°C by passive diffusion. 
Values of 340/380 fluorescence excitation ratio at 495 nm emission wavelength were 
measured. The steady-state fluorescence intensities using the Ca2+ -insensitive excitation 
wavelength of 367 nm, are presented in Table 3. 
Treatment 340/380 fluorescence 
excitation ratio 
Fluorescence excited 
at 367 nm 
Number of coverslips 
Control 1.25 ±0.06 355 ± 20 51 
Ap[l-42] 1.39 ±0.04 367 ± 22 18 
Ap[l-40] 1.37 ±0.06 360 ±18 9 
Ap[25-35] 1.38 ±0.05 358 ± 16 12 
Ap[31-35] 1.41 ±0.04 373 ± 17 12 
Table 3. Results of fluorescence measurements. 
The ratio of the 495 nm fluorescence intensities excited at 340 nm and 380 nm 
(340/380 fluorescence excitation ratio) was consistently higher in treated cells as compared to 
their untreated counterparts. Importantly, no significant alteration was detectable in Fura-2 
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fluorescence using the Ca2+ -insensititive excitation wavelength of 367 nm, indicating that the 
observed response reflects a real change in the Ca2+ concentration in the cells. During the 8-
hour incubation period, the treated and untreated cell populations were cultured in media of 
identical composition except for the presence or absence of the P-amyloid peptides. The 
observed difference in the 340/380 fluorescence excitation ratio of Fura-2-loaded cells can be 
exclusively associated with the presence or absence of Ap peptide. All the peptides 
investigated induced similar cellular responses, suggesting that the [31-35] region of the 
peptide sequence could be the putative active centre of the molecule. 
Co-treatment of the cells with equimolar concentration of ZM6 peptide, an analogue 
of the [31-34] sequence, was found to antagonise the AP[ 1-42]-induced increase in the 
340/380 fluorescence excitation ratio, leaving the Ca2+-insensitive 367 nm fluorescence 
unchanged (Table 4). 
Treatment 340/380 fluorescence 
excitation ratio 
Fluorescence excited 
at 367 nm 
Number of coverslips 
Control 1.22 ±0.06 355 ±18 16 
Ap[l-42] 1.41 ±0.05 359 ±21 16 
ZM6 1.26 ±0.04 361 ± 17 16 
AP[l-42]+ZM6 1.28 ±0.04 358 ±19 16 
Table 4. Effect of ZM6 peptide on the Ap[l-42] induced change in the 340 nm/380 nm 
fluorescence excitations ratios and steady state fluorescence intensities at 367 nm excitation. 
4.3.2. Study of antagonistic effects by microdialysis method 
Infusion of ZM6 in the MBN elicited a significant extracellular elevation of Asp, Glu 
and taurine, with postponed peak response 40 min after the start of peptide infusion. 
Following a short excitatory response, excess extracellular Asp and Glu levels returned to the 
control value. In contrast, Ap[l-42] infusion in the MBN elicited sustained elevation of 
excitatory amino acids, which was apparently present between 10 and 60 min following 
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dialysis of AP[l-42]. AP[l-42] induced extensive increases in Asp and Glu concentrations 
with an abrupt onset. 60 min after the start of Ap[l-42] infusion in the MBN, the extracellular 
amino acid levels gradually decreased and returned to the baseline level after 100 min. ZM6 
exerted a characteristic pharmacological action as it significantly decreased Ap[ 1-42]-induced 
elevations of Asp concentration and eventually abolished Ap[l-42]-induced enhanced Glu 
release. Pre-treatment with ZM6 did not influence the release profile of taurine, as peak 
taurine concentrations after either a combined ZM6 + Ap[l-42] or single Ap[l-42] 
administration did not differ significantly from each other. Reversed administration of AP[1-
42] + ZM6 did not result in any noticeable antagonistic effect (Figure 3). 
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Figure 3. Loss of cholinergic 
(AChE-positive) projection 
fibers 14 days postsurgery as 
a consequence of AP[l-42] 
infusion into the MBN and the 
neuroprotective effects of the 
ZM6. Six sham-operated, six 
AP(l-42)-infused and four 
ZM6 + AP(l-42)- infused rats 
were used. 
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4.3.3. Behavioural tests 
Assessment of spontaneous behaviours 24 h postlesion revealed a pronounced increase 
in the openfield latencies of AP[l-42]-infused animals, compared with other groups 
examined. In parallel with the changes of start latency, Ap[ 1-42]-treated rats exhibited 
markedly decreased horizontal motor activities compared with both sham-control and ZM6 + 
Ap[l-42]-treated rats, whereas rearing parameters did not change as a consequence of Ap[l-
42] infusion. Ap[l-42] microdyalisis in the MBN resulted in sever disturbances of passive 
avoidance learning, which were indicated by significantly decreased post-shock latency 
periods of Ap[ 1-42]-infused animals, whereas ZM6 attenuated the behavioural dysfunctions. 
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Infusion of A(3[l-42] in the MBN elicited a significant loss AChE-positive projection fibres in 
the somatosensory cortex, compared with all other experimental groups investigated, which 
was effectively antagonised by ZM6 pre-treatment (Figure 4). 
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Figure 4. The effects of 
AP[l-42] on novelty-induced 
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4.3.4. Effect of Ap[l-40] on transmembrane potential of cultured M26-1F cells measured by 
flowcytometry 
Cultured M26-1F cells were labelled by passive diffusion on incubation with 2 pM 
bis-oxonol for 10 min at 25 °C. The cells were exposed to a 1 pM final concentration of 
Ap[l-40] for 20 min. The effect of Ap[l-40] peptide on the resting transmembrane potential 
was monitored by means of comparative cytofluorimetric studies. The flowcytometric 
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measurements demonstrated that the distribution of the individual cell-associated probe 
fluorescence was shifted to lower levels in cells treated with Ap[l-40] for 20 min as 
compared with that of their untreated counterparts (Figure 5, left panel). A change in the 
fluorescence intensity in the same direction was caused by valinomycin, whereas gramicidin 
induced a shift to higher fluorescence intensities (Figure 5, right panel). Valinomycin is a K+-
specific ionophore known to induce hyperpolarisation [145], whereas gramicidin is a channel-
forming Na+/K+-ionophore causing rapid collapse of the transmembrane potential [146]. 
Unfortunately, this method did not show adequate sensitivity to characterise and to 
compare peptides with supposed antagonist effects. 
F l u o r e s c e n c e i n tens i t y F l u o r e s c e n c e i n tens i t y 
Figure 5. Representative flow-cytofluorimetric histograms of M26-1F cells with 1 pM Ap[l-
40] (left panel) and 1 pM valinomycin or gramicidin D (right panel). 
4.4. Stability studies on A[3[25-35] peptide 
Some amyloid derived peptides show their toxic effects only after a long 'aging' 
period performed several days at pH 7.4 and 37 °C for cluster formation. Only the high 
aggregated, polymeric forms of Ap peptides are neurotoxic; monomers show some 
neuromodulatory effects. "Aging" of Ap peptides is a common method before in vivo 
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experiments [130, 131, 132], In vitro investigations of Ap neurotoxicity in cell and tissue 
cultures proceed for several hours or even days [133, 134] at pH 7.4, 37 °C. However, these 
long "aging" and incubation processes could result in degradation of Ap peptides which 
contain Asn and Met in the peptide sequence. It is known that spontaneous cleavage occurs at 
the peptide bond adjacent to Asn [132,147,148,149], 
Stability investigations were carried out under physiological conditions in the presence 
or absence of Ca . Each experiment was repeated three times. The rate of degradation in the 
repeated experiments was similar. The possibility of biological degradation can be precluded 
because of the use of NaN3 and sterilised water in sterile and sealed vials. 
The investigations were first performed in distilled water and under physiological ion 
conditions at 37 °C in the presence 
of Ca2+. It was found that, in distilled water at 37 °C 
Ap[25-35] was stable without any signs of decomposition, even after 5 days (Figure 6). 
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Figure 6. HPLC-chromatogram of 
AP[25-35] after a 5-day incubation in 
distilled water. 
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At physiological ion concentration and in buffer solution at pH 7.4, AP[25-35] was 
stable during the first 12 h at 37°C, but after 19 h a new peak appeared in the RP-HPLC 
chromatogram (Figure 7, left panel). After 5 days, more than 50% of the peptide was 
decomposed. (Figure 7, right panel). 
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Figure 7. HPLC-chromatograms of A[3[25-35] after 19 hours (left panel) and after 5 days 
(right panel) under physiological conditions. AP[25-35] peptide is denoted by letter A, 
Ap[28-35] peptide by letter B and Ap[28-35](Met-0) by letter C. 
The compounds which represent peaks on the analytical HPLC were isolated and 
lyophilised, and their Rt values were compared with those of the following synthetic 
fragments of Ap[25-35]: Ap[27-35], Ap[28-35], Ap[31-35] and Ap[25-30], These fragments 
were synthesised as reference standards for HPLC and Ms (Table 5). The presence of the 
peptide fragment Ap[28-35] (Mw= 800) and the absence of the fragments Ap[27-35], Ap[31-
35] and Ap[25-30] were demonstrated. Mass spectrometry revealed the Ca2+ salts of the 
peptides Gly-Ser-Asn-OH and Gly-Ser-Asp-NH2 (identical molecular weight: Mw = 276), 
Ap[28-35] and the oxidised form of Ap[28-35] (Mw =816). 
At pH 7.0 only slight decomposition was observed. Experiments were also 
carried out at pH 8.0 in phosphate buffer, both in the presence and in the absence of Ca2+. The 
results indicated that the degradation process accelerates at pH > 7.0 and in the presence of 
Ca2+ (Figure 8). 
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Mass spectra 
Fragments of Ap 
Molecu ar mass 
Calculated 
(average mass) 
Formed 
Ap[25-35]-NH2 1059.29 1059.0 
Ap[28-35]-NH2 801.06 800.0 
Ap[27-35]-NH2 915.16 915.0 
Ap[25-30]-NH2 531.57 531.0 
AP[25-30]-OH 532.57 532.0 
Ap[30-35]-NH2 615.83 615.0 
Ap[31-35]-NH2 544.76 544.0 
Ap[25-27]-NH2 275.22 275.0 
Table 5. Molecular mass values of Ap fragments. 
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Figure 8. HPLC-chromatograms of AP[25-35] after incubation for 66 hours in a pH 8.0 
buffer either in the absence (left panel) or presence of Ca2+ (2 mM, right panel). 
Stability investigations under argon atmosphere were performed in the absence of 
Ca2+. The results suggest that the oxidation of Met can be avoided under these conditions. 
Degradation of the peptide chain occurs at only a very low rate (Figure 9). 
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Figure 9. HPLC-chromatogram of 
Ap[25-35] (denoted by letter A) after 
storage for 52 hours under an argon 
atmosphere at pH=8.0, in the absence of 
Ca2+. 
5. Discussion 
5.1. Synthesis of Ap peptides 
Synthesis of a peptide with a well defined sequence of amino acids is a fairly complex 
process. Formation of the peptide bond through solid-phase peptide synthesis (SPPS) is the 
most commonly applied procedure. It is based on the stepwise addition of a-amino or side-
chain protected amino acids to an insoluble polymeric support. The peptide can be cleaved as 
a peptide amide or acid, depending of linker to the resin. For N-a protection several blocking 
groups were recommended. The acid-sensitive Boc group, applied from the earliest days of 
SPPS, remained in a position of near-monopoly. Adaptation of the base-sensitive Fmoc group 
appears to be much more successful, especially in case of difficult peptide sequences. In 
addition, the repetitive deprotection steps of the Fmoc-chemistry do not require TFA, which 
can lead to alteration of the peptide bond and acid catalysed side-reactions. Moreover, 
anhydrous HF, the generally used cleaving agent in case of Boc-chemistry, is highly toxic and 
reactive, environmentally dangerous. In case of Fmoc-chemistry, cleavage of the peptide-resin 
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bond and simultaneous deprotection is carried out by TFA. However, Boc-chemistry is much 
more economical as Fmoc-chemistry. 
In order to obtain high peptide purity, purification with HPLC is required. Purification 
of poor soluble peptides is a difficult problem. Moreover, the use of TFA as acidic ion-pairing 
agent can results peptides as TFA-salts which caused us difficulties by FT-IR spectroscopy 
measurements. 
The Ap sequence is a typical "difficult peptide", due to the strong interchain stacking, 
with P-sheet conformation [14,66,150,151,152,153,154,155]. This phenomenon also occurs 
on the resin and causes low reagent accessibility during synthesis, which accounts for the 
poor coupling efficiencies [156]. 
Fortunately, in some cases, especially for short but poorly soluble peptides a very 
precise and cautious synthesis resulted, before purification, peptides with purity more then 
96% and made needless the purification of the peptide (e.g. ZM6). On the other hand, in case 
of peptides with difficult structures, manually synthesis must be preferred against an 
automatic peptide synthesiser in order to verify all amino acid couplings during the synthesis 
and according to necessity, to repeat the coupling. 
5.2. Biological investigations 
The main goal was to determine the minimum sequence with biological effects of the 
AP and to get peptides which might protect from the neurotoxic effect. It is noteworthy to 
mention the homology of the C-terminal five amino acids (IIGLM) of the AP[25-35] 
sequence with the C-terminal five amino acids (XXGLM, where X is an apolar amino acid) of 
tachykinins. The partially overlapping peptides were designed with special emphasis on this 
sequence. A series of modified peptide fragments were designed, synthesized, and 
investigated with various biological methods. The peptide with code ZM6 showed the best 
antagonistic effect. To the best of our knowledge, ZM6 was the first AP analogue capable of 
preventing the AP[ 1-42]-induced long-term elevation in [ C a 2 + ] j [143]. Moreover, ZM6 was 
found to protect cholinergic MBN neurons against AP[ 1-42]-induced neuronal damage. The 
underlying mechanism of the neuroprotective action of ZM6 might entail ligand-like 
displacement of AP[l-42] binding from its hypothetical receptor [157]. Further we found that 
R-ZM6 peptide, the Arg analog of ZM6 and the KLVGF (KLV6) sequence proved to be 
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much more active antagonists then the mother compound. These lead compounds opened the 
way for designing effective A0 antagonists, peptides and peptidomimetics. 
On the other hand, Ap peptides exert neurotoxic effects in aggregated form. Only the 
highly aggregated, polymeric form of Ap peptides are neurotoxic; monomers show some 
neuromodulatory effects. Above a threshold concentration, Ap undergoes highly ordered 
protein aggregation in aqueous solutions resulting e.g. in the formation of senile plaque in AD 
[30]. Following P- and y-secretase-mediated catabolism of APP, Ap, released in a monomelic 
form in the extracellular space, begins a self-aggregation process. Synthetic peptides even 
from different batches from the same laboratory may exhibit significant differences in 
neurotoxic activity, therefore it is necessary to determine what parameters influence the 
aggregation of Ap peptides in vitro [158]. Also, our results demonstrated the importance of 
peptide sequence to the aggregation ability: MOD-3 peptide, which has mostly hydrophilic 
amino acids in the sequence, shows a minimal tendency for aggregation. In contrary, the 
aggregation ability of MOD-4 and AP[l-42] are similar [159]. 
5.3. Stability of AP peptides 
Deamidation of Asn residues is a major nonenzymatic degradation pathway for many 
peptides and proteins: this intrinsic instability serves as "molecular clock". Our studies show 
that Ap[25-35] is not stable under physiological conditions: the peptide chain is hydrolysed at 
Asn27 resulting in isomer tripeptide fragments (AP[25-27] with Asn or isoAsn at the C-
terminal end) and the octapeptide AP[28-35] [160]. The cleavage mechanism may involve 
formation of a succinimide ring as described for other peptides [147,161] (Figure 10). 
The cleavage of the peptide chain is also affected by the presence of Ca2+ ions: 
increased Ca2+-comlexation facilitates degradation and peptide bond cleavage. It is interesting 
that this Asn-Lys sequence has not been described in the literature for being sensitive to 
hydrolysis under mild conditions. As Ap[25-35] undergoes a relatively rapid decomposition 
at pH 7.4 if the buffer contains Ca2+ ions, long incubation times and "aging" processes of Ap 
peptides should be avoided. According to our results, the method of choice would be a 
relatively short (24 hours) incubation of Ap[l-42] at pH 7.4 in aqueous solution, but without 
Ca2+ ions and under argon atmosphere in order to avoid oxidation of Met35 [130]. 
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(R-Asp-NH2 
or 
R-Asp) 
RNH 
(R-Asn 
or 
R-Asp) 
(C-terminal cyclic imide 
or 
C-terminal cyclic anhydride) 
(R-Asn-R' 
or 
R-Asp-R') 
Figure 10. Proposed mechanism for cleavage at Asn (X=N, n=2) [161]. 
Our results support the necessity of stability studies of the peptides used in different 
biological experiments. 
6. Summary and conclusions 
The main findings of the PhD thesis are as follows: 
1. Ap[l-40], Ap[l-42], two of its modified analogues, and several Ap fragments were 
synthesized. The purified peptides were analytically characterized with HPLC, amino 
acid analysis and electrospray mass spectrometry. The synthesized peptides were used 
for stability studies, secondary-structure investigations and for biological experiments. 
1/a. The solid phase synthesis of long Ap peptides was optimized using Fmoc-chemistry and 
10% anisol as an additive and deaggregating agent during the synthesis. This new 
method resulted in the best yields and purity known up to now. 
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2. Several in vitro and in vivo methods were applied (sometimes with some changes) for the 
measurement of the neurotoxicity of Ap peptides as well as well the neuroprotective 
effect of short Ap fragments and analogs (functional antagonists). 
3. Fluorimetric studies using the Ca2+ sensitive fluorescent probe Fura-2 AM demonstrated 
that rat astroglial cells treated with full-length Ap peptides and its shorter fragments 
containing the sequence Ap[31-35] and caused a long-term elevation of [ C a 2 + ] j . The 
observed change can be considered as a long-term cell physiological action and can be 
used as a sensitive marker for testing for long-term activities of Ap peptides. 
Peptide Pr-IIGL-amide (ZM6) was the first described peptide capable to reduce the 
PA[ 1-42]-induced long-term elevation in [Ca2+]j. This method can be adequate for 
testing several numbers of peptides with potentially antagonistic effects. Using 
microdialysis probes, by in vivo experiments were given further proofs of the 
neuroprotecting action of the ZM6 peptide. 
3/a. We have designed and synthesized two new pentapeptides with very good 
neuroprotective effect, the KLVGF-amide and RUGL-amide peptides. These 
compounds act as Ap-antagonists also in very small amounts and serve as leads for 
further drug design. 
4. Long aging of AP[25-35] under physiological conditions in the presence of Ca2+ resulted 
in peptide bond cleavage between Asn27 and Lys28. The Asn-Lys sequence has not been 
described previously in the literature for being sensitive to hydrolysis under mild 
conditions. In distilled water at 37 °C, all the investigated Ap peptides were stabile 
without any signs of decomposition even after aging for 7 day. For a long-term "aging" 
of peptides it can be recommended the incubation under argon atmosphere. 
5. The aggregation ability of AP[l-42] and the MODS peptide, which does not contain the 
toxic fragment AP[31-35] and has mainly hydrophobic residues, are similar. In contrary, 
MODS peptide, which has mostly hydrophilic amino acids in the molecule, but contains 
the sequence of AP[31-35], shows a minimal tendency for aggregation. 
43 
7. References 
1. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allg Zeit Psychiat Psych-
Gerich Med (1907) 64: 146-148. 
2. Mattson M.P., Chan S.L., Duan W. Modification of brain aging and neurodegenerative 
disorders by genes, diet, and behaviour. Physiol Rev (2202) 82: 637-672. 
3. Checler F. Processing of the ß-Amloid Precursor Protein and its regulation in Alzheimer's 
disease. JNeurochem (1995) 65: 1431-1441. 
4. Brining S.K. Predicting the in vitro toxicity of synthetic beta-amyloid (1-40). Neurobiol 
Aging (1997) 18: 581-589. 
5. Iraizoz I., Guiharro J.L., Gonzalo L.M., de Lacalle S. Neuropathological changes in the 
nucleus basalis correlate with clinical measures of dementia. Acta Neuropathol (1999) 98: 
186-196. 
6. De Strooper B., König G. An inflammatory drug prospect. Nature (2001) 44: 159-160. 
7. Pitschke M., Prior R., Haupt M., Riesner D. Detection of single amyloid ß-protein 
aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation 
spectroscopy. Nat Med (1998) 4: 832-834. 
8. Pluta R., Barcikowska M., Januszewski S., Misicka A., Lipkowski A.W. Evidence of 
blood-brain barrier permeability/ leakage for circulating human Alzheimer's ß-amyloid-(l-
42)-peptide. NeuroReport (1996) 7: 1261-1265. 
9. Banks W.A., Kastin A.J., Maness L.M., Banks M.F., Shayo M., McLay R.N. Interactions 
of ß-amyloids with the blood-brain barrier. Ann NY Acad Sei (1997) 826: 190-199. 
10. Kamal A., Almenar-Queralt A., LeBlanc J., Roberts E.,A., Goldstein L.S. Kinesin-
mediated axonal transport of membrane compartment containing ß-secretase and 
presenilin-1 requires APP. Nature (2001) 414: 643-648. 
11. Scharnagl H., Tisljar U., Winkler K., Huttinger M., Nauck M.A., Gross W., Wieland H., 
Ohm T.G., Marz W. The ßA4 amyloid peptide complexes to and enhances the uptake of 
ß-very low density lipoproteins by the low density lipoprotein receptor-related protein 
and heparan sulfate proteoglycans pathway. Lab Invest (1999) 79: 1271-1286. 
12. Kontush A., Donarski N., Beisiegel U. Resistance of human cerebrospinal fluid to in vitro 
oxidation is directly related to its amyloid-beta content. Free Radic Res (2001) 35: 507-
514. 
13. Ellis R.J., Pinheiro T.J.T. Danger - misfolding proteins. Nature (2002) 416: 483-484. 
14. Barrow C.J., Zagorski M.G. Solution structures of ß-peptide and its constituent fragments: 
relation to amyloid deposition. Science (1991) 253: 179-182. 
15. Glenner G.G., Wong C.W. Alzheimer's disease: initial report of the purification and 
characterization of a novel amyloid protein. Biochem Biophys Res Commun (1984) 120: 
885-890. 
16. Gibson P.H., Doughty L.A. An electron microscopic study of inclusion bodies in synaptic 
terminals of scrapie-infected animals. Acta Neuropathol (1989) 77: 420-425. 
17. Gruber A.D. Linke R.P. Generalized AA-amyloidosis in a bat. Vet Pathol (1996) 33: 428-
430. 
18. Johnstone E.M., Chaney M.O., Norris F.H., Pascual R., Little S.P. Conservation of the 
sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other 
mammals by cross-species polymerase chain reaction analysis. Mol Brain Res (1991) 10: 
299-305. 
19. Morys J., Narkiewicz O., Macjewska B., Wegiel J., Wisniewski H.M. Amyloid deposits 
and loss of neurons in the claustrum of the dog. Neuroreport (1994) 5: 1825-1828. 
20. Zagorski M.G., Barrow, CJ. NMR studies of amyloid ß-peptides: proton assignments, 
secondary structure, and mechanism of an a-helix - ß-sheet conversion for a homologous, 
28-residue, N-terminal fragment. Biochemistry (1992) 31: 5621-5631. 
44 
21. Geisel 0., Linke R.P. Key features for the diagnosis and treatment of amyloidosis in 
animals. Tierarztl Umschau (1997) 52: 655-658. 
22. Glenner G.G. Amyloid deposits and amyloidosis. The P-fibrilloses. (Part I and II) Engl J 
Med (1980) 302:1283-1292 and 1333-1343. 
23. Glenner G.G., Eanes E.D., Bladen H.A., Linke R.P., Termine I.D. P-pleated sheet fibrils. 
JHistochem Cytochem (1974) 22: 1141-1158. 
24. Smith R.P., Higuchi D.A., Broze G.J. Jr. Platelet coagulation XIa-inhibitor, a form of 
Alzheimer amyloid precursor protein. Science (1990) 248:1126-1128. 
25. Van Nostrand W.E., Schmaier A.H., Farrow J.S., Cunningham D.D. Protease nexin-H 
(amyloid P-protein precursor): a platelet a-granule protein. Science (1990) 248: 745-748. 
26. Pardridge W.M., Premachandra B.N., Fierer G. Transport of thyroxin bound to human 
prealbumin into rat liver. Am J Physiol (1985) 248: G545-G550. 
27. Moya K.L., Benowitz L.I., Schneider G.E., Allinquant B. The amyloid precursor protein 
is developmentally regulated and correlated with synaptogenesis. Dev Biol (1994) 161: 
597-603. 
28. Whitson J.S., Selkoe D.J., Cotman C.W. Amyloid P-protein enhances the survival of 
hippocampal neurons in vitro. Science (1989) 243: 1488-1490. 
29. Mattson M.P., Barger S.W., Cheng B., Lieberburg I., Smith-Swintosky V.L., Rydel R.E. 
P-Amyloid precursor protein metabolites and loss of neuronal Ca2+ homeostasis in 
Alzheimer's disease. Trends Neurosci (1993) 16: 409-414. 
30. Koo E.H., Lansbury P.T., Kelly J.W. Amyloid diseases: abnormal protein aggregation in 
neurodegeneration. Proc Natl Acad Sci USA (1999) 96: 9989-9990. 
31. Soto C. Alzheimer's and prion disease as disorders of protein conformation: implications 
for the design of novel therapeutic approaches. JMolMed (1999) 77: 412-418. 
32. Gorevic P., Goni F., Pons-Estel B., Alvarez F., Peress R., Frangione B. Isolation and 
partially characterization of neurofibrillary tangles and amyloid plaque cores in 
Alzheimer's disease: immunohistological studies. J Neuropathol Exp Neurol (1986) 45: 
647-664. 
33. Selkoe D.J., Abraham C.R., Podlisny M.B., Duffy L.K. Isolation of low-molecular-weight 
proteins from amyloid plaque fibers in Alzheimer's disease. J Neurochem (1986) 146: 
1820-1834. 
34. Dickson D.W. The pathogenesis of senile plaques. J Neuropathol Exp Neurol (1997) 56: 
321-339. 
35. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci (1997) 20: 
154-159. 
36. Morris C.J. Relationship of plaques and tangles to Alzheimer's disease phenotype. in: 
Pathobiology of Alzheimer's disease. (Goate A.M. and Ashall F., eds) Academic Press 
(Harcourt Brace and Co. Publishers), London (1995) 193-223. 
37. Martin L.J., Sisodia S.S., Koo E.H., Cork L.C., Dellovade T.L., Weidmann A., Beyreuther 
K., Masters C., Price D.L. Amyloid precursor protein in aged nonhuman primates. Proc 
Natl Acad Sci USA (1991) 88: 1461-1465. 
38. Roberts G.W., Gentleman S.M., Lynch A., Murray L., Landon M., Graham D.I. P-
Amyloid protein deposition in the brain after severe head injury: implications for the 
pathogenesis of Alzheimer's disease. J Neurol Neurosurg Psychiat (1994) 57: 419-425. 
39. Kontush A. Amyloid-p: an antioxidant that becomes a pro-oxidant and critically 
contributes to Alzheimer's disease. Free Rad Biol Med (2001) 31: 112.-1131. 
40. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron (1991) 6: 487-498. 
41. Checler F. Processing of the p-amyloid precursor protein and its regulation in Alzheimer's 
disease. J Neurochem (1995) 65: 1431-1444. 
42. Haass C., Selkoe D.J. Cellular processing of P-amyloid precursor protein and the genesis 
of amyloid P-peptide. Ce//(1993) 75: 1039-1042. 
43. Seubert P., Oltersdorf T., Lee M.G., Barbour R., Blomquist C., Davis D.L., Bryant K., 
Fritz L.C., Galasko D., Thai L.J. Secretion of P-amyloid precursor protein cleaved at the 
amino terminus of the P-amyloid peptide. Nature (1993) 361:260-263. 
45 
44. Kang J., Lemaire H.G., Unterbeck A., Salbaum J.M., Masters C.L., Grzeschik K.H., 
Multhaup G., Beyreuther K., Muller-Hill B. The precursor of Alzheimer's disease amyloid 
A4 protein resembles a cell-surface receptor. Nature (1987) 325: 733-736. 
45. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. 
Amyloid plaque core protein in Alzheimer's disease and Down syndrome. Proc Natl Acad 
Sci USA (1985) 82: 4245-4249. 
46. Braak H., Braak E. Diagnostic criteria for neuropathology assessment of Alzheimer's 
disease. Neurobiol Aging (1997) 18: S85-S88. 
47. Shea T.B., Prabhakar S., Ekinci F.J. P-Amyloid and ionophore A23187 evoke x 
hyperphosphorylation by distinct intracellular pathways: differential involvement of the 
calpain/protein kinase C system. JNeurosci Res (1997) 49: 759-768. 
48. Milton N.G. Phosphorylation of amyloid-beta at the serine 26 residue by human cdc2 
kinase. 
49. Muller U., Kins S. APP on the move. Trends Molec Med (2002) 8: 152-155. 
50. Beyreuther K. Molecular biology of Alzheimer's disease pA4 Amyloid Precursor Protein. 
ZMBH Report 1994/95: 19-26. 
51. Pollwein P. Overlapping binding sites of two different transcription factors in the 
promoter of the human gene for the Alzheimer amyloid precursor protein. Biochem 
BiophysRes Commun (1993) 190: 637-647. 
52. Borchardt T., Camakaris J., Cappai R., Masters C.L., Beyreuther K., Multhaup G. Copper 
inhibits P-amyloid production and stimulates the non-amyloidogenic pathway of 
amyloid-precursor protein secretion. Biochem J {1999) 344: 461-467. 
53. White A.R., Multhaup G., Mahler F., Bellingham S., Camakaris J., Zheng H., Bush A.I., 
Beyreuther K., Masters C.L., Cappai R. The Alzheimer's disease amyloid precursor 
protein modulates copper-induced toxicity and oxidative stress in primary neuronal 
cultures. JNeurosci (1999) 19: 9170-9179. 
54. Garzon-Rodriguez W., Sepulveda-Beccera M., Milton S., Glabbe C.G. Soluble amyloid 
AP-(l-40) exists as a stable dimer at low concentrations. J Biol Chem (1997) 272: 21037-
21044. 
55. Tjernberg L.O., Callaway D.J.E., Tjernberg A., Hahne S., Lillehook C., Terenius L., 
Thyberg J., Nordstedt C. A molecular model of Alzheimer amyloid beta-peptide fibril 
formation. J Biol Chem (1999) 274: 12619-12625. 
56. Walsh D.M., Hatley D.M., Kusumoto Y., Fezoui Y., Condron M.M., Lomakin A., 
Benedek G.B., Selkoe D.J., Teplow D.B. Amyloid p-protein fibrillogenesis. Structure and 
biological activity of protofibrillar intermediates. J Biol Chem (1999) 274: 25945-25952. 
57. Harper J.D., Lansbury P.T. Jr. Models of amyloid seeding in Alzheimer's disease and 
scrapie: mechanistic truth and physiological consequences of the time-dependent 
solubility of amyloid proteins. Annu Rev Neurosci (1997) 66: 385-407. 
58. Harper J.D., Wong S.S., Lieber C.M., Lansbury P.T. Observation of metastable Ap 
amyloid protofibrils by atomic force microscopy. Chem Biol (1997) 4: 119-125. 
59. Harper J.D., Lieber C.M., Lansbury P.T. Jr. Atomic force microscopic imaging of seeded 
fibril formation and fibril branching by the Alzheimer's disease amyloid-P protein. Chem 
Biol (1997) 4: 951-959. 
60. Penke B., Harkany T. Physiological role of amyloid precursor protein (APP) and peptide, 
in: Molecular Pathomechanisms and New Trends in Drug Research (Taylor & Francis 
Books eds.) (2002) 387-402. 
61. Gorevic P.D., Castano E.M., Sarma R., Frangione B. Ten to fourteen residue peptides of 
Alzheimer's disease protein are sufficient for amyloid fibril formation and its 
characteristic x-ray diffraction pattern. Biochem Biophys Res Commun (1987) 147:854-
862. 
62. Halverson K., Fraser P.E., Kirschner D.A., Lansbury P.T. Jr. Molecular determinants of 
amyloid deposition in Alzheimer's disease: conformational studies of synthetic P-protein 
fragments. Biochemistry (1990) 29: 2639-2644. 
46 
63. Otvos L. Jr., Szendrei G.I., Lee V.M.-Y., Mantsch M.M. Human and rodent Alzheimer P-
amyloid peptides acquire distinct confirmations in membrane-mimicking solvents. Eur J 
Biochem (1993) 211: 249-257. 
64. Tomski S.J., Murphy R.M. Kinetics of aggregation of synthetic P-amyloid peptide. Arch 
Biochem Biophys (1992) 294: 630-638. 
65. Tjenberg L.O., Lilliehôôk C., Callaway D.J., Nâslund J., Hahne S., Thyberg J., Terenius 
L., Nordstedt C. Controlling amyloid P-peptide fibril formation with protease-stable 
ligands. J Biol Chem (1996) 272: 12601-12605. 
66. Hilbich C., Kisters-Woike B., Reed J., Masters C.L., Beyreuther K. Aggregation and 
secondary structure of synthetic amyloid PA4 peptides of Alzheimer's disease. J Mol Biol 
(1991)218:149-163. 
67. Barrow C.J., Zagorski M.G. Solution structures of P peptide and its constituent fragments: 
relation to amyloid deposition. Science (1991) 253: 179-182. 
68. Atwood C.S., Moir R.D., Huang X., Scarpa R.C., Bacarra N.M.E., Romano D.M., 
Hartshorn M.A., Tanzi R.E., Bush A.I. Dramatic aggregation of Alzheimer Ap by Cu(II) 
is induced by conditions representing physiological acidosis. J Biol Chem (1998) 273: 
12817-12826. 
69. Matsuzaki K., Horikiri C. Interactions of amyloid P-peptide (1-40) with ganglioside-
containing membranes. Biochemistry (1999) 38: 4137-4142. 
70. Kása P., Rakonczay Z., Gulya K. The cholinergic system in Alzheimer's disease. Prog 
Neurobiol (1997) 52: 511-535. 
71. Luiten P.G.M., Gaykema R.P.A., Traber J., Spencer D.G. Jr. Cortical projection patterns 
of magnocellular basal nucleus subdivisions as revealed by anterogradely transported 
Phaseolus vulgaris leucoagglutinin. Brain Res (1987) 413: 229-250. 
72. Bartus R.T., Dean R.L., Beer B., Lippa S. The cholinergic hypothesis of geriatric memory 
dysfunction. Science (1982) 217: 408-414. 
73. Combus C.K., Bates P., Karlo J.C., Landreth G.E. Regulation of beta-amyloid stimulated 
proinflammatory responses by peroxisome proliferator-activated receptor-alpha. 
Neurochem (2001) 39: 449-457. 
74. Hull M., Lieb K., Fiebich B.L. Pathways of inflammatory activation in Alzheimer's 
disease: potential tagets for disease modifying drugs. CurrMed Chem (2002)1: 83-88. 
75. Keller J.N., Mattson M.P. Roles of lipid peroxidation in modulation of cellular signaling 
pathways, cell dysfunction, and cell death in nervous system. Rev Neurosci (1998) 9: 
105-116. 
76 Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radie Biol 
Med (1997) 23: 134-147. 
77. Behl C. Effects of glucocorticoids on oxidative stress-induced hippocampal cell-death: 
implications for the pathogenesis of Alzheimer's disease. Exp Gerontol (1998) 33: 689-
696. 
78. Hensley K., Carney J.M., Mattson M.P., Aksenova M., Harris M., Wu J.F. Floyd R.A. 
Butterfield D.A. A model for P-amyloid aggregation and neurotoxicity based on free 
radical generation by the peptide: relevance to Alzheimer's disease. Proc Natl Acad Sci 
USA (1994) 91: 3270-3274. 
79. Pike C.J., Walencewitz-Wasserman A.J., Kosmoski J., Cribbs D.H., Glabe C.G., Cotman 
C.W. Structure activity analyses of P-amyloid peptides: contributions of the [325-35 
region to aggregation and neurotoxicity. J Neurochem (1995) 64: 253-265. 
80. Varadarajan S., Yatin S., Kanski J., Jahanshahi F., Butterfield D.A. Methionine residue 35 
is important in amyloid p-peptide-associated free radical oxidative stress. Brain Res Bull 
(1999) 40: 133-141. 
81. Luo Y., Sunderland T., Roth G.S., Wolozin B. Physiological levels of P-amyloid peptide 
promote PC12 cell proliferation. Neurosci Lett (1996) 217: 125-128. 
82. Yankner B.A., Duffy L.K., Kirschner D.A. Neurotrophic and neurotoxic effects of 
amyloid P protein: reversal by tachykinin neuropeptides. Science (1990) 250: 279-282. 
83. Behl C., Davis J.B., Klier F.G., Schubert D. Amyloid P peptide induces necrosis rather 
than apoptosis. Brain Res (1994) 645: 253-264. 
47 
84. Ivins K.J., Bui E.T., Cotman C.W. (3-Amyloid induces local neurite degeneration in 
cultured hippocampal neurons: evidence for neuritic apoptosis. Neurobiol Dis (1998) 5: 
365-378. 
85. Harada J., Sugimoto M. Activation of caspase-3 in P-amyloid-induced apoptosis of 
cultured rat cortical neurons. Brain Res (1999) 842: 311-323. 
86. Kelly J.F., Furukawa K., Barger S.W., Rengen M.R., Mark R.J., Blanc E.M., Roth G.S., 
Mattson M.P. Amyloid P-peptide disrupts carbachol-induced muscarinic cholinergic 
signal transduction in cortical neurons. Proc Natl Acad Sci USA (1996) 93: 6753-6758. 
87. Auld D.S., Kar S., Quiron R. P-Amyloid peptides as direct cholinergic neuromodulators: a 
missing link? Trends Neurosci (1998) 21: 4349. 
88. Harkany T., Lengyel Z., Soos K., Penke B., Luiten P.G.M., Gulya K. Cholinotoxic effects 
of p-amyloid(M2) peptide on cortical projections of the rat nucleus basalis magnocellularis. 
Brain Res (1995) 685:71-75. 
89. Giovanelli L., Scalli C., Faussone Pellegrini M.S., Pepeu G., Casamenti F. Long-term 
changes in the aggregattion state and toxic effects of P-amyloid injected into the rat brain 
Neuroscience (1998) 87: 349-357. 
90. Joseph R., Han E. Amyloid P protein fragment 25-35 causes activation of cytoplasmic 
calcium in neurons. Biochem Biophys Res Commun (1992) 184:1441-1447. 
91. Mattson M.P., Cheng B., Davis D., Bryant K., Lieberburg I., Rydel R.E. P-Amyloid 
peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to 
excitotoxicity. J Neurosci (1992) 12: 376-389. 
92. Behl C. Alzheimer's disease and oxidative stress: implications for novel therapeutic 
approches. Prog Neurobiol (1999) 57: 301-323. 
93. Polleri A., Gianelli M.V., Murialdo G. Dementia: a neuroendocrine perspective. J 
Endocrinol Invest^2002) 25: 73-83. 
94. De Keyser J., Suiter G., Luiten G.P.M. Clinical trials with neuroprotective drugs in acute 
ischaemic stroke: are we doing the right thing? Trends Neurosci (1999) 22: 535-540. 
95. Lipton S.A., Nakanishi N. Shakespeare in love - with NMD A receptors? Nat Med (1999) 
5:270-271. 
96. Poduslo J.F., Curran G.L., Sanyal B., Selkoe D.J. Receptor-mediated transport of human 
amyloid P-protein 1-40 and 1-42 at the blood-brain barrier. Neurobiol Dis (1999) 6: 190-
199. 
97. Yan S., Zhu H., Fu J., Roher A., Tourtellotte W.W., Rajavashisth T., Godman G.C., Stem 
D., Schmidt A.M. Amyloid-P peptide - receptor for advanced glycation endproduct 
interaction elicits neuronal expression of macrophage-colony stimulating factor: a 
proinflammatory pathway in Alzeimer's disease. Proc Natl Acad Sci USA (1997) 94: 5296-
5301. 
98. El Khoury J., Hickman S.E., Thomas C.A., Cao L.,Silverstein S.C., Loike J.D. Scavenger 
receptor-mediated adhesion of microglia to P-amyloid. Nature (1996) 382: 716-719. 
99. Yan S.D., Chen X., Fu J., Zhu H., Roher A., Slattery T., Zhao L., Nagashima M.,Morser 
J., Migheli A., Naworth P., Stem D., Schmidt A.M. RAGE and amyloid-p peptide 
neurotoxicity in Alzheimer's disease. Nature (1996)382: 685-691. 
100. Mattson M.P., Rydel R.E. Amyloid ox-tox transducers. Nature (1996) 382: 674-675. 
101. Graves A.B., Rosner D., Echeverria D., Mortimer J.A., Larson E.B. Occupational 
exposure to solvents and estimated risk of Alzheimer's disease. Occup Envirom Med 
(1998) 55(9): 627-633. 
102. Katzman R., Kawas C.H. The epidemiology of Alzheimer disease, in: Alzheimer 
Disease. (Terry R.D., Katzman R., BickK.L., eds.), Raven Press, New York, 105-122. 
103. Selkoe D.J. Alzheimer's Disease: genes, proteins and therapy. Physiol Rev (2001) 81: 
741-766. 
104. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen 
G.S., Roses A.D. Proc Natl Acad Sci USA (1993) 90: 1977-1981. 
105. Dickson D.W., Ivanushkin A., Heitner J., Yen S.H., Davies P. Apolipoprotein E 
immunoreactivity is increased in amyloid deposits of Alzheimer's disease, but not 
pathological aging or diffuse Lewy disease. In K Iqbal, J.M. Mortimer, B Winbald and 
48 
H.M Wisniewski (Eds.) Research Advances in Alzheimer's Disease and Related Disorders, 
Wily, Chichester, 1995, pp. 371-383. 
106. Bao F., Arai H., Matsushita S., Higuchi S., Sasaki H. Expression of apolipoprotein E in 
normal and diverse neurodegenerative disease brain. Neuroreport (1996) 7: 1733-1739. 
107. Härtig W., Brückner G., Schmidt C., Brauer K., Bodewitz G., Turner J.D., Bigl V. Co-
localization of ß-amyloid peptides, apolipoprotein E and glial markers in senile plaques in 
the prefrontal cortex of old rhesus monkeys. Brain Res (1997) 751: 315-322. 
108. Goate A., Chartier-Harlin M.C., Mullan M., Brown J., Crawford F., Fidani L., Guiffra 
L., Haynes A., Irving N., James L., Mant R., Newton P., Rooke K., Roques P., Talbot C., 
Willimson R., Rossor M., Owen M., Hardy J. Segregation of a missense mutation in the 
amyloid precursor protein gene with familial Alzheimer's disease. Nature (1991) 349: 704-
706. 
109. Van-Dujin C.M., Stijnen T., Hofinan A. Risk factors Alzheimer's disease: overview of 
the EURODEM collaborative re-analysis of case-control studies. ERODEM Risk Factors 
Research Group. Int J Epidemiol (1991) 20: S4-S12. 
110. Mortimer J.A., van Duijn C.M., Chandra V., Fratiglioni L., Graves AB., Heyman A., 
Jorm A.F., Kokmen E., Kondo K., Rocca W.A. Head trauma as a risk factor for 
Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk 
Factors Research Group. Int J Epidemiol (1991) 20: S28-S35. 
111. Roberts G.W., Gentleman S.M., Lynch A., Graham D.I. ßA4 amyloid protein deposition 
in brain after head trauma. Lancet (1991) 338: 1422-1423. 
112. Devanand DP, Michaels-Marston KS, Liu X, Pelton GH, Padilla M, Marder K, Bell K, 
Stem Y, Mayeux R. Olfactory deficits in patients with mild cognitive impairment predict 
Alzheimer's disease at follow-up. Am J Psychiatry (2000) 157:1399-1405. 
113. Cruts M., Van Broeckhoven C. Molecular genetics of Alzheimer's disease. Ann Med 
(1999) 30: 560-565. 
114. Ritchie K., Dupuy A.M. The current status of apo E4 as a risk factor for Alzheimer's 
disease: an epidemiological perspective. Int J Geriatr Psychiatry (1999) 14: 695-700. 
115. Muir J.L. Acetylcholine, aging and Alzheimer's disease. Pharmacol Biochem Behav 
(1997) 56: 687-696. 
116. Tolnay M., Probst A. Tau protein pathology in Alzheimer's disease and related 
disorders. Neuropathol Appl Neurobiol (1999) 171-187. 
117.Davis K.L. Alzheimer's disease: seeking new ways to preserve brain function. Geriatrics 
(1999) 54: 42-47. 
118. Sramek J.J., Cutler N.R. Recent developments in the drug treatment of Alzheimer's 
disease. Drugs Aging (1999) 14: 359-373. 
119. McGeer P.L., Schulzer M., McGeer E.G. Arthritis and anti-inflammatory agents as 
possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. 
Neurology (1996) 47: 425-432. 
120. Stewart W.F., Kawas C., Corrada M., Metter E.J. Risk of Alzheimer's disease and 
duration of NSAID use. Neurology (1997) 48: 626-632. 
121. Weggen S., Eriksen J.L., Das P., Sagl S.A., Wang R., Pletrzik C.U., Findlay K.A., Smith 
T.E., Murphy M.P., Bulter T., Kang D.E., Marquez-Sterling M., Golde T.E., Koo E.H. A 
subset of NSAIDs lower amyloidogenic Aß42 independently of cyclooxygenase activity. 
Nature (2001) 414: 212-216. 
122. De Strooper B., König G. An inflammatory drug prospect. Nature (2001) 414: 159-160. 
123. Morris M.C., Beckett L.A., Scherr P.A., Hebert L.E., Bennett D.A., Field T.S. Evans 
D.A. Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. 
Alzheimer Disease Assoc Disorders (1998)12: 121-126. 
124. Mattson M.P. Modification of ion homeostasis by lipid peroxidation: roles in neuronal 
degeneration and adaptive plasticity. Trends Neurosci (1998) 21:53-57. 
125. Mark R.J., Ashford J.W., Goodman Y., Mattson M.P. Anticonvulsants attenuate amyloid 
ß-peptide neurotoxicity, Ca2+deregulation, and cytoskeletal pathology. Neurobiol Aging 
(1995) 16: 187-198. 
49 
126. Janka Z. Therapeutic alternatives in the medication of Alzheimer's dementia, in Clin 
Neurosci, (1998), pp. 17., 4th Hungarian Conference on Alzheimer's disease and Related 
Disorders. 
127. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., 
Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberbug I., Motter R., 
Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., 
Yednock T., Games D., Seubert P. Immunization with amyloid-P attenuates Alzheimer-
disease-like pathology in the PDAPP mouse. Nature (1999) 400: 173-177. 
128. Check E. Nerve inflammation halts trial for Alzheimer's drug. Nature (2002) 415: 462. 
129. Sugaya K., Brannen C.L. Stem cell strategies for neuroreplacement therapy in 
Alzheimer's disease. Med Hypotheses (2001) 6: 697-700. 
130. Wood S.J., Maleeff B., Hart T., Wetzel R. Selective inhibition of Ap fibril formation. 
Mol Biol (1995) 256: 870-877. 
131. Café C., Torri C., Bertorelli L., Angretti N., Lucca E., Forloni, G., Marzatico F. 
Oxidative stress after acute and chronic application of beta-amyloid fragment 25-35 in 
cortical cultures. Neurosci Letters (1996) 203: 61-65. 
132. Maurice T., Lockhart B.P., Privat A. Amnesia induced in mice by centrally administered 
beta-amyloid peptides involves cholinergic dysfunction. Brain Res (1996) 706:191-193. 
133. Gray C.W., Patel A.J. Neurodegeneration mediated by glutamate and beta-amyloid 
peptide: a comparison and possible interaction. Brain Res (1995) 691: 169-179. 
134. Scorziello A., Meucci O., Florio T., Fattore M., Forloni G., Salmona M., Schettini G. 
Beta 25-35 alters calcium homeostasis and induces neurotoxicity in cerebellar granule 
cells. JNeurochem (1996) 66: 1995-2003. 
135. Friedman A.R., Ichhpurani A.K., Brown D.M., Hillman R.M., Krabill L.F., Martin R.A., 
Zurcher-Neely H.A., Guido D.M. Degradation of growth hormone releasing factor analogs 
in neutral aqueous solution is related to deamidation of asparagine residues. Int J Pept Prot 
Res (1991) 37: 14-20. 
136. Szendrei G.I., Prammer K.V., Otvos L. Effects of aspartic acid isomerization on 
conformation, antibody recognition and serum stability of amyloid P-peptide N-terminal 
decapeptide. In: Peptides: Chemistry, Structure and Biology (1996), Mayflower 
Scientific Ltd., (Eds P.T.P. Kaumaya and R.S. Hodges), 258-260. 
137. Kaiser E., Colescott R.L., Bossinger C.D., Cook P.I. Color test for detection of free 
terminal amino groups in the solid-phase synthesis of peptides. Anal Biochem (1970) 34: 
595-598. 
138. Vojkovsky T. Detection of secondary amines on solid phase. Pept Res (1995) 8: 236-
237. 
139. Grynkiewicz G., Poenie M., Tsien R.Y.A new generation of Ca2+ indicators with greatly 
improved fluorescence properties. J Biol Chem (1985) 260: 3440-3445. 
140. Harkany T., O'Mahony S., Kelly J.P., Soós K., Toro I., Penke B., Luiten P.G.M., Nyakas 
Cs., Gulya K., Leonard B.E. p-Amyloid (Phe(S03)H)2425-35 in rat nucleus basalis 
magnocellularis induces behavioural dysfunctions, impairs learning and memory and 
disrupts cortical cholinergic innervation. Behav Brain Res (1998) 90: 133-145. 
141. Giordano M., Takashima H., Herranz A., Poltorak M., Geller H.M., Marone M., Freed 
W.J. Immortalized GABAergic cell lines derived from rat striatum using temperature-
sensitive allele of the SV40 large T antigen. Exp Neurol (1993) 124:395-400. 
142. Tjemberg L.O., Náslund J., Lidquist F., Johannson J., Karlstrom A.R., Thyberg J., 
Terenius L., Nordstedt C. Arrest of P-amyloid fibril formation by a pentapeptide ligand. J 
Biol Chem (1996) 271: 8545-8548. 
143 Laskay G., Zarándi M., Varga J., Jost K., Fónagy A., Torday Cs., Latzkovits L.,Penke B. 
A putative tetrapeptide antagonist prevents P-amyloid-induced long-term elevation of 
[Ca 2 + ] i in rat astrocytes. Biochem Biophys Res Commun (1997) 235: 479-481. 
144. Shen C.L., Murphy R.M. Solvent effects on self-assembly of beta-amyloid peptide. 
Biophys J, (1995) 69: 640-651. 
50 
145. Hoffman J.F., Laris P.C. Determination of membrane potentials in human and amphiuma 
red blood cells by means of fluorescent probe. J Physiol (1974) 239: 519-552. 
146. Wagonner A.S. Dye indicators of membrane potential. Ann Rev Biophys Bioeng (1979) 
8: 47-68. 
147. Capasso S., Mazzarella L., Sorrentino G., Balboni G., Kirby A.J. Kinetics and 
mechanism of the cleavage of the peptide bond next to asparagine. Peptides (1996) 17: 
1075-1077. 
148. Aswad D.W., Paranandi M.V., Schurter B.T. Isoaspartate in peptides and proteins: 
formation, significance, and analysis. JPharm BiomedAnal. (2000) 21:1129-1236. 
149. Goolcharran C, Stauffer L.L., Cleland J.L., Borchardt R.T. The effects of a histidine 
residue on the C-terminal side of an asparaginyl residue on the rate of deamidation using 
model pentapeptides. JPharm Sci. (2000), 89:818-825. 
150. Barrow C.J., Yasuda A., Kenny P.T., Zagorsky M.G. Solution conformations and 
aggregational properties of synthetic amyloid P-peptides of Alzheimer's disease. J Mol 
Biol (1992) 225: 1075-1093. 
151. Burdick D., Soreghan B., Kwon M., Kosmoski M.J., Knauer M., Henschen A., Yates J., 
Cotman C., Glabe C. Assembly and aggregation properties of synthetic Alzheimer's A4/p 
amyloid peptide analogs. J Biol Chem (1992) 267: 546-554. 
152. Fraser P.E., Nguyen J.T., Inouye H., Surewicz W.K., Selkoe D.J., Podlisny M.B., 
Kirschner D.A. Fibril formation by primate, rodent and Dutch-hemorrhagic analogues of 
Alzheimer amyloid beta-protein. Biochemistry (1992) 31: 10716-10723. 
153. Hilbich C., Kisters-Woike B., Reed J., Masters C.L., Beyreuther K. Substitutions of 
hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease beta A/4 
peptides. J Mol Biol (1992) 228: 460-43. 
154. Hilbich C., Kisters-Woike B., Reed J., Masters C.L., Beyreuther K. Human and rodent 
sequence analogues of Alzheimer's amyloid pA4 share similar properties and can be 
solubilized in buffers ofpH 7.4. EurJBiochem (1991) 201: 6169. 
155. Kirschner D.A., Inouye H., Duffy L.K., Sinclair A., Lind M., Selkoe D.J. Synthetic 
peptide homologous to beta protein from Alzheimer disease forms amyloid-like fibrils in 
vitro. Proc Natl Acad Sci USA (1984) 84: 6953-6957. 
156. Quibell M., Turnell W.G., Johnson T. Preparation and purification of P-amyloid (1-43) 
via soluble, amide backbone protected intermediates. J Org Chem (1994) 59: 1745-1750. 
157. Harkany T., Ábrahám I., Laskay G., Timmerman W., Jost K., Zarándi M., Penke B., 
Nyakas Cs., Luiten P.G.M. Propionyl-IIGL tetrapeptide antagonizes P-amyloid 
excitotoxicity in rat nucleus basalis. Neuroreport (1999) 10: 1-6. 
158. Szabó Z., Klement É., Jost K., Zarándi M., Soós K., Penke B. An FT-IR study of the p-
amyloid conformation: standardization on aggregation grade. Biochem Biophys Res 
Commun (1999) 265: 297-300. 
159. Szabó Z., Jost K., Soós K., Zarándi M., Kiss J.T., Penke B. Solvent effect on 
aggregational properties of P-amyloid polypeptides studied by FT-IR spectroscopy. J 
Molec Structure (1999) 480: 481-487. 
160. Jost K., Varga J. Penke B., Zarándi M. In vitro degradation of P-amyloid [25-35] 
peptide. Protein Peptide Lett (2001) 8:423-428. 
161. Bongers J., Heimer E.P., Lambros T., Pan Y.E., Campbell R.M., Felix A.M. Degradation 
of aspartic acid and asparagine residues in human growth hormone-releasing factor. Int J 
PeptProtRes (1992): 39: 364-374. 
51 
8. Acknowledgements 
I am very grateful to Professor Botond Penke, PhD, DSc, academician, for his 
continuous support and for providing me the opportunity to work as PhD student at the 
Department of Medical Chemistry, University of Szeged. 
I am especially thankful to my PhD supervisor Márta Zarándi, PhD for personal 
guidance and for introducing me in such a challenging research area as the peptide chemistry. 
I always enjoyed her optimistic attitude to the scientific problems, and I benefited much from 
her zest and purposefulness. 
I thank Dr. Tibor Harkány, Dr. Zoltán Kele, Dr. Zoltán Szabó, Dr. Lajos Tóth and 
especially Dr. József Varga for their kind support and collaboration during my work. 
I thank Professor Andrea R. Horváth, the head of Department of Clinical Chemistry, 
University of Szeged, for her continuous support in writing this PhD thesis. 
I thank Mrs. Katalin Nagy, Mrs. Rita Ábrahámné Szendrei, Ms. Éva Dósai Molnár and 
Mr. Richard Ferenczi for their helpful technical assistance. 
Finally, I wish to thank the enthusiastic support of my family. 
52 
9. Annex 
Publications related to the subject of the Thesis 
